[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 89 of about 89
1. Pineda CE, Welton ML: Management of anal squamous intraepithelial lesions. Clin Colon Rectal Surg; 2009 May;22(2):94-101
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal squamous intraepithelial lesions.
  • Anal squamous intraepithelial lesions include both low-grade squamous intraepithelial lesions (LSIL) and high-grade squamous intraepithelial lesions (HSIL) and are caused by chronic infection with the human papillomavirus (HPV).
  • The disease is increasing in both incidence and prevalence, especially among patients with the following risk factors: homosexual men, acquired or iatrogenic immunosuppression, and presence of other HPV-related diseases.
  • Although the natural history of the disease is unknown, there is significant evidence that untreated HSIL progresses to squamous cell carcinoma in 11% of patients and in up to 50% of patients with extensive disease and immunosuppression.
  • Anal cytology and reflex HPV DNA testing are used to screen for disease, particularly among patients with the aforementioned risk factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):782-5 [3652891.001]
  • [Cites] Genitourin Med. 1994 Feb;70(1):22-5 [8300094.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1610-5 [15577418.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Minerva Chir. 2008 Oct;63(5):389-99 [18923350.001]
  • [Cites] Am J Epidemiol. 1996 Nov 15;144(10):916-23 [8916502.001]
  • [Cites] Dis Colon Rectum. 1977 Oct;20(7):570-2 [913212.001]
  • [Cites] BMJ. 1993 Feb 13;306(6875):419-22 [8461721.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415-22 [9170415.001]
  • [Cites] Am J Surg. 1979 Feb;137(2):231-4 [371426.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Am J Surg. 1954 Nov;88(5):710-4 [13197672.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1221-7 [14520450.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1332-6; discussion 1336-8 [14530670.001]
  • [Cites] Arch Surg. 2004 Mar;139(3):259-61 [15006881.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):263-75 [15137956.001]
  • [Cites] Clin Infect Dis. 2004 May 15;38(10):1490-2 [15156490.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):915-20 [15220697.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • [Cites] J Am Acad Dermatol. 2005 Apr;52(4):603-8 [15793509.001]
  • [Cites] Int J Colorectal Dis. 2006 Mar;21(2):135-42 [15864603.001]
  • [Cites] J Low Genit Tract Dis. 2004 Oct;8(4):272-5 [15874871.001]
  • [Cites] J Surg Res. 2005 Jul 1;127(1):8-13 [15964301.001]
  • [Cites] Diagn Cytopathol. 2005 Sep;33(3):152-6 [16078257.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):126 [16222485.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):36-40 [16283561.001]
  • [Cites] Australas J Dermatol. 2006 May;47(2):120-3 [16637809.001]
  • [Cites] AIDS. 2006 May 12;20(8):1151-5 [16691066.001]
  • [Cites] Int J STD AIDS. 2007 Feb;18(2):77-80 [17331275.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):565-75 [17380365.001]
  • [Cites] Rev Assoc Med Bras. 2007 Mar-Apr;53(2):147-51 [17568919.001]
  • [Cites] Gynecol Oncol. 2007 Sep;106(3):453-60 [17586030.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1410-5; discussion 1415-6 [17710507.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 Sep;21(8):1054-60 [17714124.001]
  • [Cites] J Low Genit Tract Dis. 2007 Oct;11(4):201-22 [17917566.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):2-9 [18030528.001]
  • [Cites] Acta Cytol. 2007 Nov-Dec;51(6):893-9 [18077982.001]
  • [Cites] Am Surg. 2007 Dec;73(12):1279-83 [18186390.001]
  • [Cites] Sex Transm Dis. 2008 Feb;35(2):197-202 [18216727.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2078-83 [18273049.001]
  • [Cites] Int J STD AIDS. 2008 Feb;19(2):118-20 [18334066.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1130-6 [18481150.001]
  • [Cites] Int J STD AIDS. 2008 Jul;19(7):445-9 [18574114.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] Adv Anat Pathol. 2008 Sep;15(5):263-78 [18724100.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Br J Surg. 1999 Aug;86(8):1063-6 [10460644.001]
  • [Cites] Dis Colon Rectum. 2000 Mar;43(3):346-52 [10733116.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2114-9 [11966386.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • [Cites] Am Fam Physician. 2003 Nov 15;68(10):1992-8 [14655809.001]
  • [Cites] AIDS. 2004 Jul 23;18(11):1561-9 [15238774.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):919-28 [9269808.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]
  • [Cites] Ann Surg Oncol. 2008 May;15(5):1470-5 [18299937.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1447-56 [15726546.001]
  • [Cites] Sex Transm Infect. 2005 Apr;81(2):142-6 [15800092.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5273-80 [16033846.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1133-6 [16044425.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):715-7 [16916390.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] Dis Colon Rectum. 2007 Jul;50(7):1011-6 [17429713.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):32-9 [18667921.001]
  • [Cites] Dis Colon Rectum. 1988 Jun;31(6):419-22 [3288448.001]
  • (PMID = 20436833.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780238
  • [Keywords] NOTNLM ; Anal squamous dysplasia / high-grade squamous intraepithelial lesions / high-resolution anoscopy
  •  go-up   go-down


2. Salit IE, Tinmouth J, Chong S, Raboud J, Diong C, Su D, Sano M, Lytwyn A, Chapman W, Mahony J: Screening for HIV-associated anal cancer: correlation of HPV genotypes, p16, and E6 transcripts with anal pathology. Cancer Epidemiol Biomarkers Prev; 2009 Jul;18(7):1986-92
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for HIV-associated anal cancer: correlation of HPV genotypes, p16, and E6 transcripts with anal pathology.
  • BACKGROUND: HIV-positive men with a history of anal-receptive intercourse are at risk for anal cancer.
  • We determined whether human papilloma virus (HPV) biomarkers were correlated with anal pathology in these men.
  • The number of HPV genotypes per anal swab was higher for anal intraepithelial neoplasia (AIN) 2/3 than for normal or AIN 1 histology [median, 5 types (interquartile range) (IQR), 3-7 versus 3.5 (IQR), 2-6; P = 0.0005].
  • In the multivariable logistic regression model, HPV genotypes 16 [odds ratio, 2.58; 95% confidence interval (95% CI), 1.31-5.08; P = 0.006] and 31 (odds ratio, 4.74; 95% CI, 2.00-11.22; P = 0.0004), baseline CD4 count < 400 cells/mm(3) (odds ratio, 2.96; 95% CI, 1.46-5.99; P = 0.0025), and Acquired Immunodeficiency Syndrome (AIDS)-defining illness (odds ratio, 2.42; 95% CI, 1.22-4.82; P = 0.01) were associated with high-grade histology after adjusting for age.
  • CONCLUSIONS: The presence of high-grade anal pathology (AIN 2/3) in HIV-positive men was associated with multiple HPV genotypes, HPV genotypes 16 and 31, and HPV 16 viral load.
  • [MeSH-major] Alphapapillomavirus / genetics. Anus Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Genes, p16. HIV Seropositivity / virology. Oncogene Proteins, Viral / genetics. Repressor Proteins / genetics
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. AIDS-Related Opportunistic Infections / virology. DNA, Viral / analysis. Genotype. Homosexuality, Male. Humans. Male. Papillomavirus Infections / complications. Papillomavirus Infections / epidemiology. Papillomavirus Infections / pathology. Papillomavirus Infections / virology. Risk Factors. Viral Load

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19567510.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / E6 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Repressor Proteins
  •  go-up   go-down


3. Simard EP, Pfeiffer RM, Engels EA: Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med; 2010 Aug 9;170(15):1337-45
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of cancer risk late after AIDS onset in the United States.
  • BACKGROUND: Persons living with AIDS today remain at elevated cancer risk.
  • We conducted this study to assess long-term cancer risk among persons with AIDS relative to the general population and the impact of HAART on cancer incidence.
  • METHODS: Records of 263 254 adults and adolescents with AIDS (1980-2004) from 15 US regions were matched to cancer registries to capture incident cancers during years 3 through 5 and 6 through 10 after AIDS onset.
  • Rate ratios (RRs) were used to compare cancer incidence before and after 1996 to assess the impact of availability of HAART.
  • RESULTS: Risk was elevated for the 2 major AIDS-defining cancers: Kaposi sarcoma (SIRs, 5321 and 1347 in years 3-5 and 6-10, respectively) and non-Hodgkin lymphoma (SIRs, 32 and 15).
  • Risk was elevated for all non-AIDS-defining cancers combined (SIRs, 1.7 and 1.6 in years 3-5 and 6-10, respectively) and for the following specific non-AIDS-defining cancers: Hodgkin lymphoma and cancers of the oral cavity and/or pharynx, tongue, anus, liver, larynx, lung and/or bronchus, and penis.
  • Anal cancer incidence increased between 1990-1995 and 1996-2006 (RR, 2.9; 95% confidence interval [CI], 2.1-4.0), as did that of Hodgkin lymphoma (RR, 2.0; 95% CI, 1.3-2.9).
  • CONCLUSION: Among people who survived for several years or more after an AIDS diagnosis, we observed high risks of AIDS-defining cancers and increasing incidence of anal cancer and Hodgkin lymphoma.
  • [MeSH-minor] Adolescent. Adult. Anus Neoplasms / epidemiology. Anus Neoplasms / virology. Bronchial Neoplasms / epidemiology. Bronchial Neoplasms / virology. Female. Humans. Incidence. Laryngeal Neoplasms / epidemiology. Laryngeal Neoplasms / virology. Liver Neoplasms / epidemiology. Liver Neoplasms / virology. Lung Neoplasms / epidemiology. Lung Neoplasms / virology. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / virology. Male. Middle Aged. Mouth Neoplasms / epidemiology. Mouth Neoplasms / virology. Penile Neoplasms / epidemiology. Penile Neoplasms / virology. Risk Assessment. Risk Factors. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / virology. Time Factors. United States / epidemiology. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1227-35 [11423255.001]
  • [Cites] Ann Intern Med. 2009 Feb 17;150(4):283-4; author reply 284-5 [19221387.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4 [19357635.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5737-42 [19336755.001]
  • [Cites] Stat Med. 2000 Feb 15;19(3):335-51 [10649300.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Oct 1;25(2):115-23 [11103041.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] AIDS. 2004 Jul 2;18(10):1393-401 [15199315.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Am J Public Health. 1995 Nov;85(11):1552-5 [7485671.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]
  • [Cites] Lancet. 1998 Jun 6;351(9117):1682-6 [9734884.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] JAMA. 1999 Jun 23-30;281(24):2305-15 [10386555.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41 [10430217.001]
  • [Cites] Clin Infect Dis. 2005 Feb 1;40(3):490-1 [15668878.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] AIDS Educ Prev. 2005 Dec;17(6 Suppl B):39-48 [16401181.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1383-8 [16549832.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34 [16878047.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):642-8 [16868538.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Ann Epidemiol. 2008 Mar;18(3):230-4 [18083545.001]
  • [Cites] HIV Med. 2008 Apr;9(4):196-202 [18366443.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [CommentIn] Arch Intern Med. 2010 Aug 9;170(15):1345-6 [20696959.001]
  • (PMID = 20696958.001).
  • [ISSN] 1538-3679
  • [Journal-full-title] Archives of internal medicine
  • [ISO-abbreviation] Arch. Intern. Med.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010150-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS212628; NLM/ PMC2921231
  •  go-up   go-down


Advertisement
4. Mackesy-Amiti ME, McKirnan DJ, Ouellet LJ: Relationship characteristics associated with anal sex among female drug users. Sex Transm Dis; 2010 Jun;37(6):346-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship characteristics associated with anal sex among female drug users.
  • BACKGROUND: Anal sex is an important yet little studied HIV risk behavior for women.
  • METHODS: Using information collected on recent sexual encounters, we examined the influence of sex partner and relationship characteristics on the likelihood of engaging in anal sex among women with a high risk of HIV infection.
  • RESULTS: Anal sex was nearly 3 times more common among actively bisexual women (OR = 2.96, 95% CI: 2.17-4.03).
  • Women were more likely to have anal sex with partners who injected drugs (OR = 2.32, 95% CI: 1.44-3.75), were not heterosexual (OR = 1.85, 95% CI: 1.18-2.90), and with whom they exchanged money or drugs for sex (OR = 1.79, 95% CI: 1.10-2.90).
  • The likelihood of anal sex also increased with the number of nights sleeping together (OR = 1.15, 95% CI: 1.06-1.24).
  • In contrast, emotional closeness and social closeness were not associated with anal sex.
  • Condom use during anal sex was uncommon, and did not vary according to partner or relationship characteristics.
  • CONCLUSIONS: Our findings support the need for HIV prevention interventions that target anal sex among heterosexuals, particularly in drug-using populations residing in neighborhoods with elevated levels of HIV prevalence.

  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Addiction. 2004 Jul;99(7):885-96 [15200584.001]
  • [Cites] Aging Ment Health. 2003 Nov;7(6):462-8 [14578008.001]
  • [Cites] JAMA. 1987 Aug 14;258(6):788-90 [3475478.001]
  • [Cites] Arch Sex Behav. 1991 Jun;20(3):233-76 [2059146.001]
  • [Cites] Arch Intern Med. 1991 Dec;151(12):2411-6 [1684098.001]
  • [Cites] AIDS. 1993 Sep;7(9):1247-54 [8216983.001]
  • [Cites] Am J Epidemiol. 1995 Oct 15;142(8):864-74 [7572963.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jul;12(3):282-9 [8673532.001]
  • [Cites] N Engl J Med. 1997 Apr 10;336(15):1072-8 [9091805.001]
  • [Cites] NIDA Res Monogr. 1997;167:17-36 [9243555.001]
  • [Cites] Am J Epidemiol. 1998 Apr 1;147(7):694-703 [9554609.001]
  • [Cites] Am J Epidemiol. 1998 Jul 1;148(1):88-96 [9663408.001]
  • [Cites] Am J Public Health. 1998 Aug;88(8):1265-6 [9702169.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Mar 1;20(3):295-9 [10077180.001]
  • [Cites] Sex Transm Infect. 1998 Dec;74(6):399-404 [10195047.001]
  • [Cites] AIDS Care. 2005 Jun;17 Suppl 1:S102-13 [16096122.001]
  • [Cites] Sex Transm Infect. 2005 Oct;81(5):421-5 [16199744.001]
  • [Cites] Adv Data. 2005 Sep 15;(362):1-55 [16250464.001]
  • [Cites] Sex Transm Dis. 2005 Nov;32(11):710-7 [16254547.001]
  • [Cites] AIDS Behav. 2005 Dec;9(4):403-8; discussion 409-13 [16344920.001]
  • [Cites] Am J Public Health. 2006 Jun;96(6):1066-72 [16670234.001]
  • [Cites] J Lesbian Stud. 2005;9(3):103-16 [17548289.001]
  • [Cites] Sex Transm Dis. 2007 Oct;34(10):815-9 [17551414.001]
  • [Cites] AIDS Behav. 2007 Nov;11(6):789-811 [17180724.001]
  • [Cites] J Infect Dis. 2007 Dec 15;196(12):1852-9 [18190267.001]
  • [Cites] AIDS Behav. 2008 Sep;12(5):796-805 [17653843.001]
  • [Cites] Lancet Infect Dis. 2008 Sep;8(9):553-63 [18684670.001]
  • [Cites] J Urban Health. 2009 Jul;86 Suppl 1:5-31 [19472058.001]
  • [Cites] J Urban Health. 2009 Jul;86 Suppl 1:144-8 [19513852.001]
  • [Cites] AIDS Behav. 2010 Feb;14(1):132-40 [18654844.001]
  • [Cites] J Hepatol. 1999;31 Suppl 1:92-5 [10622568.001]
  • [Cites] AIDS Patient Care STDS. 1999 Dec;13(12):717-30 [10743535.001]
  • [Cites] Arch Sex Behav. 2000 Aug;29(4):357-73 [10948725.001]
  • [Cites] Sex Transm Dis. 2000 Sep;27(8):483-9 [10987457.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Aug 1;24(4):393-8 [11015157.001]
  • [Cites] J Infect Dis. 2000 Dec;182(6):1588-94 [11069228.001]
  • [Cites] AIDS. 2001 Mar 9;15(4):534-5 [11242155.001]
  • [Cites] AIDS. 2001 Oct 19;15(15):2057-60 [11600841.001]
  • [Cites] Am J Health Behav. 2003 May-Jun;27(3):228-34 [12751619.001]
  • [Cites] Am J Public Health. 2003 Jun;93(6):902-6 [12773350.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • (PMID = 20065891.001).
  • [ISSN] 1537-4521
  • [Journal-full-title] Sexually transmitted diseases
  • [ISO-abbreviation] Sex Transm Dis
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / U01 DA017378-01; United States / NIDA NIH HHS / DA / U01 DA017377; United States / NIDA NIH HHS / DA / U01DA017394; United States / NIDA NIH HHS / DA / U01 DA017373; United States / NIDA NIH HHS / DA / U01 DA017373-01; United States / NIDA NIH HHS / DA / U01DA017377; United States / NIDA NIH HHS / DA / U01DA017373; United States / NIDA NIH HHS / DA / U01 DA017387-01; United States / NIDA NIH HHS / DA / U01 DA017387; United States / NIDA NIH HHS / DA / U01 DA017377-01; United States / NIDA NIH HHS / DA / U01DA017378; United States / NIDA NIH HHS / DA / U01DA017387; United States / NIDA NIH HHS / DA / U01 DA017394; United States / NIDA NIH HHS / DA / U01 DA017394-01; United States / NIDA NIH HHS / DA / U01 DA017378
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS352801; NLM/ PMC3278856
  •  go-up   go-down


5. Cáceres W, Cruz-Amy M, Díaz-Meléndez V: AIDS-related malignancies: revisited. P R Health Sci J; 2010 Mar;29(1):70-5
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: revisited.
  • Since the first reports between the association of Human Immunodeficiency Virus (HIV) infection and neoplasia, there has been a dramatic change in the incidence and epidemiology of AIDS-related malignancies.
  • Kaposi sarcoma (KS), non-Hodgkin's lymphomas (NHL), and cervical cancer are classified by the Centers for Disease Control and Prevention (CDC) as AIDS-defining malignancies.
  • However, since the availability of highly active combination antiretroviral therapy (cART), especially protease inhibitors, there has been a steady increase in non- AIDS defining malignancies, such as Hodgkin's lymphoma (HL), lung cancer, hepatocellular cancer, anal cancer and others and a decline in AIDS-defining neoplasias.
  • Although the emergence of non-AIDS defining cancers could be a result of longer life expectancy and due to a better control of HIV, toxic habits and co-infection with other viruses such as hepatitis B, hepatitis C and human papilloma virus (HPV) could play an important role.
  • The interactions of cART and incomplete immune reconstitution could be other factors explaining the increase in non-AIDS defining cancers.
  • These emerging non-AIDS defining malignancies present a new challenge in the care of patients with HIV infection, and require optimal treatment protocols that take into consideration the interaction between cART and systemic chemotherapy.
  • We review the current status of AIDS-related malignancies, its pathophysiology, epidemiology and management with emphasis in the changing patterns of presentation.
  • [MeSH-minor] Humans. Lymphoma, AIDS-Related / epidemiology


6. Rosa-Cunha I, Cardenas GA, Dickinson G, Metsch LR: Addressing anal health in the HIV primary care setting: a disappointing reality. AIDS Patient Care STDS; 2010 Sep;24(9):533-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Addressing anal health in the HIV primary care setting: a disappointing reality.
  • The increased risk of anal cancer among individuals living with HIV suggests that anal health (e.g., anal symptoms, anal practices, examination of the anus) should be an issue of priority for HIV care providers to discuss with their HIV-infected patients.
  • We investigated the prevalence of HIV-infected individuals discussing anal health with their HIV primary care provider and factors associated with this discussion.
  • Overall, only 22% of women, 32% of heterosexual men, and 54% of men who have sex with men (MSM) reported discussing anal health with their HIV providers in the prior 12 months.
  • In a multivariable logistic regression, when adjusting for other factors, heterosexual men and MSM were 2.31 and 5.56 times, respectively, more likely to discuss anal health with their HIV providers compared to their women counterparts.
  • Other factors associated with anal health discussion were the patients' better perception of engagement with HIV providers and having had a sexually transmitted disease exam in the past 12 months.
  • Reporting of unprotected sex with HIV-negative or unknown HIV status was inversely related to discussion of anal health with primary care providers (odds ratio [OR] = 0.53).
  • Efforts are greatly needed to increase the focus on anal health in the HIV primary care setting for both men and women.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Br J Fam Plann. 2000 Apr;26(2):89-92 [10773601.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):843-9 [11390533.001]
  • [Cites] Fam Pract. 2001 Oct;18(5):516-8 [11604374.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] Eur J Dermatol. 2003 Jul-Aug;13(4):367-71 [12948917.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Fam Pract. 2004 Oct;21(5):528-36 [15367475.001]
  • [Cites] J Infect Dis. 2004 Nov 1;190(9):1685-91 [15478076.001]
  • [Cites] Curr Opin Oncol. 1995 Sep;7(5):437-41 [8541389.001]
  • [Cites] Lancet. 1999 May 15;353(9165):1657-61 [10335785.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Med Care. 2005 Sep;43(9 Suppl):III40-52 [16116308.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5 [16280701.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] J Gen Intern Med. 2006 Jun;21(6):661-5 [16808754.001]
  • [Cites] AIDS Behav. 2006 Nov;10(6):699-705 [16639542.001]
  • [Cites] Sex Transm Dis. 2007 Mar;34(3):170-3 [16837830.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):73-81 [18066626.001]
  • [Cites] Sex Transm Dis. 2008 Feb;35(2):197-202 [18216727.001]
  • [Cites] Drug Alcohol Depend. 2008 May 1;95(1-2):37-44 [18243580.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Sex Transm Infect. 2009 Apr;85(2):148-9 [19153110.001]
  • [Cites] AIDS. 2009 Jun 1;23(9):1135-42 [19390418.001]
  • [Cites] Perspect Sex Reprod Health. 2009 Sep;41(3):142-9 [19740231.001]
  • [Cites] Arch Sex Behav. 2011 Apr;40(2):281-8 [19847636.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]
  • (PMID = 20731611.001).
  • [ISSN] 1557-7449
  • [Journal-full-title] AIDS patient care and STDs
  • [ISO-abbreviation] AIDS Patient Care STDS
  • [Language] ENG
  • [Grant] United States / PHS HHS / / 5P30A1073961; United States / NIDA NIH HHS / DA / R01DA017612-03S2; United States / NIDA NIH HHS / DA / R01DA017612; United States / NIAID NIH HHS / AI / P30 AI073961; United States / PHS HHS / / R18/CCR420971-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2958442
  •  go-up   go-down


7. Tirado-Ramos A, Saltz J, Lechowicz MJ: HIV-K: an integrative knowledge base for semantic integration of AIDS-related malignancy data and treatment outcomes. Stud Health Technol Inform; 2010;159:239-43
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-K: an integrative knowledge base for semantic integration of AIDS-related malignancy data and treatment outcomes.
  • Technological innovations such as web services and collaborative Grid platforms like caGrid can create opportunities to converge the worlds of health care and clinical research, by facilitating access and integration of HIV-related malignancy clinical and outcomes data at more sophisticated, semantic levels.
  • At the same time, large numbers of randomized clinical trial and outcomes data on AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM) have been produced during the last few years.
  • This is a white paper on work in progress from Emory University's HIV/AIDS related malignancy data integrative knowledge base project (HIV-K).
  • We are working to increase the understanding of available clinical trial data and outcomes of ADM such as lymphoma, as well as nADM such as anal cancer, Hodgkin lymphoma, or liver cancer.
  • Our hypothesis is that, by creating prototypes of tools for semantics-enabled integrative knowledge bases for HIV/AIDS-related malignancy data, we will facilitate the identification of patterns and potential new overall evidence, as well as the linking of integrated data and results to registries of interest.
  • [MeSH-major] Databases, Factual. HIV-1. Lymphoma, AIDS-Related / therapy. Semantics

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - How to Tell Patients .
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2008 Dec 1;112(12):4384-99 [19029456.001]
  • [Cites] PLoS One. 2009;4(3):e4724 [19266092.001]
  • [Cites] J Clin Exp Neuropsychol. 2010 Apr;32(4):398-407 [19763997.001]
  • [Cites] Int J STD AIDS. 1999 Dec;10(12):795-802 [10639060.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Stat Med. 1988 Nov;7(11):1121-37 [3201038.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Public Health. 2005;95 Suppl 1:S144-50 [16030331.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim [16396154.001]
  • [Cites] Bioinformatics. 2006 Aug 1;22(15):1910-6 [16766552.001]
  • [Cites] Antiviral Res. 2006 Sep;71(2-3):335-42 [16782210.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]
  • (PMID = 20543443.001).
  • [ISSN] 0926-9630
  • [Journal-full-title] Studies in health technology and informatics
  • [ISO-abbreviation] Stud Health Technol Inform
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI050409; United States / NIAID NIH HHS / AI / P30 AI050409; United States / NIAID NIH HHS / AI / P30 AI050409-11; United States / NCRR NIH HHS / RR / UL1 RR025008; United States / NCRR NIH HHS / RR / UL1 RR025008-04; United States / NCATS NIH HHS / TR / UL1 TR000454
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS315000; NLM/ PMC3157699
  •  go-up   go-down


8. Seaberg EC, Wiley D, Martínez-Maza O, Chmiel JS, Kingsley L, Tang Y, Margolick JB, Jacobson LP, Multicenter AIDS Cohort Study (MACS): Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer; 2010 Dec 1;116(23):5507-16
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007.
  • BACKGROUND: The incidence of Kaposi sarcoma (KS) and non-Hodgkin lymphoma (NHL) among human immunodeficiency virus (HIV)-infected individuals declined after the introduction of highly active antiretroviral therapy (HAART) in the mid-1990s, but the cancer risk associated with HIV infection during the HAART era remains to be clarified.
  • METHODS: Cancer incidence among HIV-infected and HIV-uninfected participants in the Multicenter AIDS (acquired immunodeficiency syndrome) Cohort Study (MACS) between 1984 and 2007 was compared with the expected incidence using US population-based data from the Surveillance, Epidemiology, and End Results (SEER) program.
  • Age- and race-adjusted cancer incidence rates were also compared HIV by status and over time within the MACS.
  • Compared with SEER, MACS HIV-infected men had significantly (P<.05) elevated rates of KS (standardized incidence ratio [SIR], 139.10), NHL (SIR, 36.80), Hodgkin lymphoma (HL)(SIR, 7.30), and anal cancer (SIR, 25.71).
  • Within MACS, HIV infection was found to be independently associated with each of these cancers across the entire follow-up period, and KS (incidence rate ratio [IRR], 54.93), NHL (IRR, 11.18), and anal cancer (IRR, 18.50) were each found to be significantly elevated among HIV-infected men during the HAART era.
  • Among these men, the incidence of KS and NHL declined (IRR, 0.13 and 0.23, respectively), the incidence of anal cancer increased (IRR, 5.84), and the incidence of HL remained statistically unchanged (IRR, 0.75) from the pre-HAART to the HAART era.
  • CONCLUSIONS: Cancer risk remains elevated among HIV-infected men who have sex with men, highlighting the continuing need for appropriate cancer screening in this population.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):446-51 [17762569.001]
  • [Cites] Ann Epidemiol. 2008 Mar;18(3):230-4 [18083545.001]
  • [Cites] AIDS. 2008 Feb 19;22(4):489-96 [18301061.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] Lancet. 2008 Jul 26;372(9635):293-9 [18657708.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):1-2 [19339933.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5737-42 [19336755.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):56-63 [15654781.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] AIDS. 2005 Nov 18;19(17):2009-18 [16260908.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1383-8 [16549832.001]
  • [Cites] Cancer. 2000 Aug 15;89(4):901-12 [10951356.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] J Clin Epidemiol. 2001 Dec;54 Suppl 1:S29-34 [11750207.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Am J Public Health. 2006 Jun;96(6):1020-7 [16670218.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):469-78 [16894295.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1725-30 [9848347.001]
  • [CommentIn] Cancer. 2010 Dec 1;116(23):5344-7 [20960526.001]
  • (PMID = 20672354.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01-AI-35043; United States / NIAID NIH HHS / AI / U01-AI-35042; United States / NCRR NIH HHS / RR / M01 RR000052-46; United States / NIAID NIH HHS / AI / U01 AI035041-17; United States / NCRR NIH HHS / RR / 5-M01-RR-00052; United States / NIAID NIH HHS / AI / U01 AI035039-17; United States / NIAID NIH HHS / AI / AI035039-17; United States / NIAID NIH HHS / AI / U01 AI035042-17; United States / NIAID NIH HHS / AI / U01-AI-35041; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NIAID NIH HHS / AI / AI035042-17; United States / NIAID NIH HHS / AI / AI035043-17; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NIAID NIH HHS / AI / AI035040-17; United States / NIAID NIH HHS / AI / U01 AI035043-17; United States / NCRR NIH HHS / RR / M01 RR000052; United States / NIAID NIH HHS / AI / U01-AI-35040; United States / NIAID NIH HHS / AI / U01 AI035040-17; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / U01-AI-35039; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NIAID NIH HHS / AI / U01 AI035039
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS218249; NLM/ PMC2991510
  • [Investigator] Margolick JB; Jacobson LP; Phair JP; Wolinsky SM; Detels R; Rinaldo CR
  •  go-up   go-down


9. Diamond C, Taylor TH, Aboumrad T, Bringman D, Anton-Culver H: Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex Transm Dis; 2005 May;32(5):314-20
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy.
  • OBJECTIVE: We sought to determine if the introduction of highly active antiretroviral therapy (HAART) corresponded with changes in anal squamous cell cancer rates among men with AIDS.
  • STUDY: We linked cancer registry data from 1988-2000 and AIDS registry data from 1981-July/2003 for San Diego County.
  • RESULTS: The annual incidence of invasive anal cancer increased from zero per 100,000 men with AIDS aged 25 to 64 years (95% confidence interval [CI], 0-226) in 1991 to 224 per 100,000 (95% CI, 102-425) in the year 2000.
  • Pre-HAART, the average annual incidence of invasive anal cancer was 49 per 100,000 men with AIDS aged 25 to 64 years (95% CI, 16-114) versus 144 per 100,000 (95% CI, 93-212) post-HAART.
  • The relative risk of invasive anal cancer among men with AIDS compared with men without known HIV/AIDS was 98 (95% CI, 36-264) pre-HAART and 352 (95% CI, 186-669) post-HAART.
  • The increased incidence of anal cancer among men with AIDS resulted in an increase in the overall rate of anal cancer among men in San Diego County.
  • CONCLUSIONS: The rising incidence of anal cancer among men with AIDS may be related to increased longevity with HAART and the consequent increased time at risk for the development of malignancy and/or the result of greater use of cytologic screening.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15849533.001).
  • [ISSN] 0148-5717
  • [Journal-full-title] Sexually transmitted diseases
  • [ISO-abbreviation] Sex Transm Dis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1K07CA096480-1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


10. Stier EA, Goldstone SE, Berry JM, Panther LA, Jay N, Krown SE, Lee J, Palefsky JM: Infrared coagulator treatment of high-grade anal dysplasia in HIV-infected individuals: an AIDS malignancy consortium pilot study. J Acquir Immune Defic Syndr; 2008 Jan 1;47(1):56-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infrared coagulator treatment of high-grade anal dysplasia in HIV-infected individuals: an AIDS malignancy consortium pilot study.
  • OBJECTIVE: To evaluate prospectively the safety of the infrared coagulator (IRC) as a treatment for anal high-grade squamous intraepithelial lesions (HSILs) in HIV-infected individuals and to seek preliminary evidence for efficacy.
  • METHODS: HIV-infected patients with </=3 biopsy-proven internal anal HSILs received office-based treatment with the IRC at participating AIDS Malignancy Consortium sites.
  • Patients were evaluated every 3 months for a year with anal cytology and HRA with biopsy.
  • No procedure-related severe adverse events were reported.
  • Twelve patients reported mild or moderate anal/rectal pain or bleeding.
  • CONCLUSIONS: The IRC is a well-tolerated method of treating discrete anal canal HSILs in HIV-infected patients.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156992.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01CA070047; United States / NCI NIH HHS / CA / U01CA071375; United States / NCI NIH HHS / CA / U01CA121947; United States / NCI NIH HHS / CA / U01CA70019; United States / NCI NIH HHS / CA / U01CA70054
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


11. Silverberg MJ, Abrams DI: AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol; 2007 Sep;19(5):446-51
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era.
  • Recent literature is reviewed with respect to the incidence and risk factors for cancer in HIV patients.
  • RECENT FINDINGS: Previous studies have demonstrated substantial declines in AIDS-defining malignancies in the era of antiretroviral therapy, with clear links to better immune function.
  • Increases in non-AIDS-defining malignancies such as Hodgkin's disease, skin, lung, anal, and kidney cancers have been noted by some but not all authors.
  • Certain non-AIDS-defining malignancies may be related to immunodeficiency, although data are conflicting.
  • SUMMARY: Non-AIDS-defining malignancies account for more morbidity and mortality than AIDS-defining malignancies in the antiretroviral therapy era.
  • Traditional risk factors play a significant role in the increased risk of non-AIDS-defining malignancies for HIV-infected individuals, but do not entirely explain the excess cancer risk.
  • Unanswered questions remain including the relationship of immunodeficiency and the risk of site-specific non-AIDS-defining malignancies, and the effect of antiretroviral therapy duration and drug class on cancer risk.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762569.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 67
  •  go-up   go-down


12. Piketty C, Kazatchkine MD: Human papillomavirus-related cervical and anal disease in HIV-infected individuals in the era of highly active antiretroviral therapy. Curr HIV/AIDS Rep; 2005 Aug;2(3):140-5
HIV InSite. treatment guidelines - Non-ARV Adverse Events .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus-related cervical and anal disease in HIV-infected individuals in the era of highly active antiretroviral therapy.
  • HIV-infected men who have sex with men remain at high risk of developing anal cancer despite the widespread use of highly active antiretroviral therapy (HAART).
  • In HIV-infected women, however, there is some evidence that HAART may be associated with regression of human papillomavirus (HPV)-related cervical disease.
  • So far, epidemiologic data provided by cancer registries have shown no reduction in the incidence of cervical and anal cancer in patients with HIV infection since the initiation of HAART in 1996.
  • Recent data suggest that HPV infection occurs in the anal canal of immunocompromised patients, as an opportunistic infection, in the absence of receptive anal intercourse.
  • Taken together, these lines of evidence support the need for developing anal and cervical cancer screening programs for patients with HIV, whether untreated or on HAART.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. Antiretroviral Therapy, Highly Active / adverse effects. Anus Neoplasms / virology. Cervical Intraepithelial Neoplasia / virology. HIV Infections / drug therapy. Neoplasms, Squamous Cell / virology. Papillomaviridae / pathogenicity. Papillomavirus Infections / etiology


13. Dhir AA, Sawant S, Dikshit RP, Parikh P, Srivastava S, Badwe R, Rajadhyaksha S, Dinshaw KA: Spectrum of HIV/AIDS related cancers in India. Cancer Causes Control; 2008 Mar;19(2):147-53
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of HIV/AIDS related cancers in India.
  • OBJECTIVE: To study the cancer pattern among HIV positive cancer cases.
  • METHOD: The study group included patients registered in the HIV Cancer clinic at the Tata Memorial Hospital (TMH), Mumbai, which is the largest tertiary referral cancer center in India.
  • We used the gender and age-specific proportions of each cancer site of the year 2002 that was recorded in the Hospital Cancer Registry to estimate an expected number of various cancer sites among HIV positive cancer patients during the period 2001-2005.
  • The observed number of site-specific cancer cases was divided by the expected number to obtain proportional incidence ratio (PIR).
  • In males, PIR was increased for anal cancer (PIR = 10.3, 95%CI 4.30-24.83), Hodgkin's disease, testicular cancer, colon cancer, and few head and neck cancer sites.
  • Among females, the PIRs for cervical cancer (PIR = 4.1, 95%CI 2.90-5.75), vaginal cancer (PIR = 7.7, 95%CI 2.48-23.85), and anal cancer (PIR = 6.5, 95%CI 0.91-45.88) were increased.
  • CONCLUSIONS: The absence of Kaposi's sarcoma and increased PIRs for certain non-AIDS defining cancers among HIV infected cancer cases indicates a different spectrum of HIV associated malignancies in this region.
  • The raised PIR for cervical cancer emphasizes the urgent need for screening programs for cervical cancer among HIV infected individuals in India.


14. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D: AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol; 2008 Oct 10;26(29):4834-42
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: state of the art and therapeutic challenges.
  • Despite the impact of combination antiretroviral therapy (cART) on HIV-related mortality, malignancy remains an important cause of death in the current era.
  • Although the advent of cART has resulted in reductions in the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma, non-AIDS-defining malignancies present an increased risk for HIV-infected patients, characterized by some common clinical features, generally with a more aggressive behavior and a more advanced disease at diagnosis, which is responsible for poorer patient outcomes.
  • Specific therapeutic recommendations are lacking for these new nonopportunistic malignancies, such as Hodgkin's lymphoma, anal cancer, lung cancer, hepatocarcinoma, and many others.
  • Special considerations of these AIDS-related and non-AIDS-related malignancies and their clinical and therapeutic aspects constitute the subject of this review.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18591544.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


15. Truesdale MD, Goldstone SE: The fear factor: drivers and barriers to follow-up screening for human papillomavirus-related anal cancer in men who have sex with men. Int J STD AIDS; 2010 Jul;21(7):482-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The fear factor: drivers and barriers to follow-up screening for human papillomavirus-related anal cancer in men who have sex with men.
  • Human papillomavirus (HPV)-related anal cancer incidence is rising in men who have sex with men (MSM).
  • Retrospective chart review identified MSM with anal dysplasia.
  • Questionnaires were completed after anal dysplasia diagnosis.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / psychology. Early Detection of Cancer / psychology. Homosexuality, Male. Papillomavirus Infections / diagnosis. Patient Compliance / statistics & numerical data

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20852198.001).
  • [ISSN] 1758-1052
  • [Journal-full-title] International journal of STD & AIDS
  • [ISO-abbreviation] Int J STD AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


16. Cranston RD, Hart SD, Gornbein JA, Hirschowitz SL, Cortina G, Moe AA: The prevalence, and predictive value, of abnormal anal cytology to diagnose anal dysplasia in a population of HIV-positive men who have sex with men. Int J STD AIDS; 2007 Feb;18(2):77-80
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevalence, and predictive value, of abnormal anal cytology to diagnose anal dysplasia in a population of HIV-positive men who have sex with men.
  • Due to the increasing incidence of anal cancer in HIV-positive men who have sex with men, and the potential to detect and treat high-grade anal dysplasia--the putative anal cancer precursor--we have introduced an anal cytology screening service.
  • Patients with abnormal anal cytology have follow-up high-resolution anoscopy (HRA) with biopsy of lesions clinically suspicious for high-grade dysplasia.
  • One hundred and sixty-four (67%) men had abnormal anal cytology, and 93 of them had follow-up HRA and anal biopsy.
  • The positive predictive value for any anal cytological abnormality to predict any degree of anal dysplasia was 95.7+/-2.1%, and for any anal cytological abnormality to predict high-grade anal dysplasia was 55.9+/-5.1%.
  • Abnormal anal cytology was highly predicative of anal dysplasia on biopsy.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms. Carcinoma, Squamous Cell. HIV Infections / complications. Homosexuality, Male
  • [MeSH-minor] AIDS-Related Opportunistic Infections / diagnosis. AIDS-Related Opportunistic Infections / epidemiology. Adult. Aged. Biopsy. Cytological Techniques. Humans. Male. Middle Aged. Predictive Value of Tests. Prevalence

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17331275.001).
  • [ISSN] 0956-4624
  • [Journal-full-title] International journal of STD & AIDS
  • [ISO-abbreviation] Int J STD AIDS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Ramírez-Marrero FA, Smit E, De La Torre-Feliciano T, Pérez-Irizarry J, Miranda S, Cruz M, Figueroa-Vallés NR, Crespo CJ, Nazario CM: Risk of cancer among Hispanics with AIDS compared with the general population in Puerto Rico: 1987-2003. P R Health Sci J; 2010 Sep;29(3):256-64
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of cancer among Hispanics with AIDS compared with the general population in Puerto Rico: 1987-2003.
  • BACKGROUND: The risk of cancer among Hispanics with Acquired Immune Deficiency Syndrome (AIDS) in the United States and Puerto Rico (PR) has not been well described.
  • The purpose of this study was to determine the risk of AIDS related and non-AIDS related cancers among Hispanics with AIDS in PR.
  • METHODS: A probabilistic record linkage of the PR AIDS Surveillance Program and PR Central Cancer Registry databases was conducted.
  • AIDS cases were grouped according to year of AIDS onset and antiretroviral therapy availability: 1987-1989 (limited availability), 1990-1995 (mono and dual therapy), and 1996-2003 (highly active antiretroviral therapy: HAART).
  • Cancer risk was described using the standardized incidence ratios (SIR).
  • RESULTS: A total of 612 cancers were identified after 3 months of AIDS diagnosis: 409 (66.7%) AIDS related and 203 (33.1%) non-AIDS related.
  • Although a decreasing trend in the risk of AIDS and non-AIDS related cancers was observed, the risk for both remained higher in the AIDS group compared to the general population in PR.
  • Non-AIDS related cancers with higher risk during the HAART availability were: oropharyngeal, anal, liver, larynx, eye and orbit, Hodgkin lymphoma, and vaginal.
  • CONCLUSION: Hispanics with AIDS in PR consistently showed a greater risk of AIDS and non-AIDS related cancers compared to the general population in PR and that has not changed over time.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20799513.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA096257; United States / NCI NIH HHS / CA / P20 CA096256
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Puerto Rico
  •  go-up   go-down


18. Abramowitz L, Benabderrahmane D, Ravaud P, Walker F, Rioux C, Jestin C, Bouvet E, Soulé JC, Leport C, Duval X: Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors. AIDS; 2007 Jul 11;21(11):1457-65
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors.
  • OBJECTIVE: To assess the prevalence of and factors associated with squamous intraepithelial lesions and condyloma [human papillomavirus (HPV)-related lesions) in HIV-infected patients.
  • INTERVENTION: A systematic examination for macroscopic HPV-related lesions through anoscopy with histological confirmation, evaluation of dysplasia and HPV typing.
  • RESULTS: Of 473 patients examined, (200 homosexual men, 123 heterosexual men, 150 women), 108 (23%) had histologically confirmed anal HPV-related lesions (36, 15 and 11% of the respective populations), including 51 (47%) with only endoanal localization.
  • Among these 108 patients, histological dysplasia of grades I or II and grade III were noted in 59 and two patients, respectively, invasive endoanal cancer in one; three patients also had high-risk oncogenicity HPV without dysplasia.
  • Independent identified associated factors of HPV-related condyloma were the number of incidents of sexual intercourse per month [odds ratio (OR) 1.04; 95% confidence interval (CI) 1.01-1.06], CD4 cell count below 200 x 10 cells/l (OR 3.22; 95% CI 1.37-7.60), history of anal HPV lesion (OR 4.57; 95% CI 2.13-9.81), and receptive anal intercourse (OR 2.30; 95% CI 1.11-4.77).
  • The two latter factors remained associated with histological dysplasia (OR 2.82; 95% CI 1.38-5.76 for history of anal condyloma, and OR 4.29; 95% CI 2.18-8.44 for receptive anal intercourse).
  • [MeSH-major] Anus Diseases / virology. Anus Neoplasms / virology. Carcinoma in Situ / virology. Condylomata Acuminata / diagnosis. HIV Infections / virology. Sexual Behavior
  • [MeSH-minor] Adult. Anal Canal / pathology. Anal Canal / virology. Cross-Sectional Studies. Female. Heterosexuality. Homosexuality. Humans. In Situ Hybridization. Male. Middle Aged. Odds Ratio. Papilloma / diagnosis. Papilloma / pathology. Papilloma / virology. Prevalence. Risk


19. Lim ST, Levine AM: Non-AIDS-defining cancers and HIV infection. Curr HIV/AIDS Rep; 2005 Aug;2(3):146-53
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-defining cancers and HIV infection.
  • With fewer patients now succumbing to infectious complications of AIDS, other HIV-related morbidities, such as malignancies, have become increasingly important.
  • Apart from Kaposi's sarcoma, non-Hodgkin's lymphoma, and cervical cancer, which are considered as AIDS-defining, several additional cancers, referred to as non-AIDS-defining cancers, are also statistically increased in HIV-infected persons.
  • These include Hodgkin's disease, anal carcinoma, lung cancer, nonmelanomatous skin cancer, and testicular germ cell tumors, among others.
  • However, the types of cancer observed at an increased frequency and the relative risks reported vary widely among studies.
  • Although immunosuppression is consistently associated with an increased risk of AIDS-related malignancies, the role of immunosuppression in the pathogenesis of non-AIDS- defining cancers is controversial.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091262.001).
  • [ISSN] 1548-3568
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


20. Bower M, Palmieri C, Dhillon T: AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis; 2006 Feb;19(1):14-9
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy.
  • PURPOSE OF REVIEW: Three cancers in people with HIV denote an AIDS diagnosis: Kaposi's sarcoma, high-grade B-cell non-Hodgkin's lymphoma and invasive cervical cancer.
  • In addition a number of other cancers occur at increased frequency in this population group but are not AIDS-defining illnesses.
  • This review discusses the impact of highly active antiretroviral therapy on the epidemiology and outcome of AIDS-defining cancers.
  • In contrast, highly active antiretroviral therapy has had little impact on the incidence of human papilloma virus-associated tumours (cervical and anal cancer) in people with HIV, although it may improve survival by reducing opportunistic infection deaths.
  • As people with HIV live longer with highly active antiretroviral therapy, an increased incidence of other non AIDS-defining cancers that have no known association with oncogenic infections is becoming apparent.
  • SUMMARY: For those with access to highly active antiretroviral therapy, the good news from the AIDS-defining cancers - particularly Kaposi's sarcoma and non-Hodgkin's lymphoma - may be balanced by the increasing numbers of non AIDS-defining cancers.
  • [MeSH-minor] Female. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / epidemiology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374212.001).
  • [ISSN] 0951-7375
  • [Journal-full-title] Current opinion in infectious diseases
  • [ISO-abbreviation] Curr. Opin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


21. Palefsky JM, Holly EA, Efirdc JT, Da Costa M, Jay N, Berry JM, Darragh TM: Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS; 2005 Sep 2;19(13):1407-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men.
  • OBJECTIVES: The incidence of anal cancer among men who have sex with men (MSM) has continued to increase since the introduction of highly active antiretroviral therapy (HAART).
  • The prevalence of the putative anal cancer precursor, anal intraepithelial neoplasia (AIN) was high among HIV-positive MSM prior to the availability of HAART but little is known about AIN since HAART was introduced.
  • A total of 357 HIV-positive MSM with no history of anal cancer completed a questionnaire detailing behaviors and medical history, anal cytology and human papillomavirus (HPV) testing, and high-resolution anoscopy with biopsy for detection of AIN.
  • RESULTS: Eighty-one percent of participants with available CD4+ cell counts at baseline had AIN of any grade; 52% had AIN 2 or 3; and 95% had anal HPV infection.
  • Our data indicate that HAART is not associated with a reduced prevalence of AIN and support measures to prevent anal cancer among HIV-positive MSM whether or not they are using HAART.
  • [MeSH-major] Anus Neoplasms / virology. Carcinoma in Situ / virology. HIV Infections / complications. Homosexuality, Male
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. Adult. Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Humans. Male. Middle Aged. Multivariate Analysis. Papillomavirus Infections / complications. Prospective Studies. Risk Factors. Viral Load

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103772.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5 M01-RR-00079; United States / NCI NIH HHS / CA / R01CA54053
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


22. Palefsky JM, Berry JM, Jay N, Krogstad M, Da Costa M, Darragh TM, Lee JY: A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS; 2006 May 12;20(8):1151-5
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals.
  • OBJECTIVES: To test a therapeutic vaccine consisting of a fusion of the human papillomavirus (HPV) 16 E7 protein and the Mycobacterium bovis heat shock protein 65 (SGN-00101) to treat high-grade anal intraepithelial neoplasia (HG-AIN) in HIV-positive individuals.
  • Anal disease was assessed at baseline, 8, 12, 24 and 48 weeks and was classified as the more severe of anal cytology and anal biopsy.
  • Anal HPV DNA was detected using L1 consensus primer-based PCR followed by type-specific probing and dot-blot hybridization (DBH).
  • RESULTS: There were no drug-related serious adverse events or significant changes in HIV viral load and CD4/CD8 ratio.
  • [MeSH-major] Anus Neoplasms / therapy. Cancer Vaccines / therapeutic use. Carcinoma in Situ / therapy. HIV Seropositivity / complications

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - HIV InSite .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16691066.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR 00079; United States / NCI NIH HHS / CA / U01 CA 70019; United States / NCI NIH HHS / CA / U01 CA 70047
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Cancer Vaccines; 0 / Chaperonin 60; 0 / Papillomavirus E7 Proteins; 0 / Recombinant Fusion Proteins; 0 / Viral Vaccines; 0 / heat-shock protein 65, Mycobacterium; EC 3.6.1.- / Chaperonins
  •  go-up   go-down


23. Richel O, Wieland U, de Vries HJ, Brockmeyer NH, van Noesel C, Potthoff A, Prins JM, Kreuter A: Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men. Br J Dermatol; 2010 Dec;163(6):1301-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men.
  • BACKGROUND: Anal intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-induced potential precursor lesion of anal cancer, is frequent among human immunodeficiency virus (HIV)-positive men who have sex with men (MSM).
  • So far, only a few prospective studies have been performed on the topical treatment of AIN, especially at the intra-anal location.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. Administration, Topical. Adult. Aged. Humans. Male. Middle Aged. Papillomavirus Infections / complications. Papillomavirus Infections / virology. Pilot Projects. Prospective Studies

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. BJD © 2010 British Association of Dermatologists.
  • (PMID = 20716208.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Nguyen ML, Farrell KJ, Gunthel CJ: Non-AIDS-Defining Malignancies in Patients with HIV in the HAART Era. Curr Infect Dis Rep; 2010 Jan;12(1):46-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-Defining Malignancies in Patients with HIV in the HAART Era.
  • The introduction of highly active antiretroviral therapy (HAART) has drastically changed the scope and spectrum of diseases associated with HIV, shifting from AIDS-related to non-AIDS-related diseases.
  • Studies linking HIV/AIDS databases to cancer registries have shown a dramatic decrease in AIDS-related malignancies and a steady increase in non-AIDS-defining malignancies (NADM).
  • Meta-analysis of published studies show an increase in NADM over the general population, mostly among infection-related cancers such as anal cancer, Hodgkin lymphoma, and liver cancer.
  • Among the non-infection-related cancers, lung and skin cancers predominate.
  • As HIV-infected individuals survive longer, better screening strategies are needed to detect cancer earlier, and prospective data are needed to assess the impact of HAART on cancer outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308498.001).
  • [ISSN] 1534-3146
  • [Journal-full-title] Current infectious disease reports
  • [ISO-abbreviation] Curr Infect Dis Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Chaiyachati K, Cinti SK, Kauffman CA, Riddell J: HIV-infected patients with anal carcinoma who subsequently developed oral squamous cell carcinoma: report of 2 cases. J Int Assoc Physicians AIDS Care (Chic); 2008 Nov-Dec;7(6):306-10
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-infected patients with anal carcinoma who subsequently developed oral squamous cell carcinoma: report of 2 cases.
  • We describe 2 patients who had human immunodeficiency virus (HIV) infection and who first developed human papillomavirus (HPV)-related anal squamous cell carcinoma and later, oral squamous cell carcinoma.
  • At the time each patient developed oral cancer, they were responding well to antiretroviral therapy with undetectable viral loads.
  • Careful screening for oral cancers may be indicated in HIV-infected patients with HPV-associated anal cancer.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. HIV Infections / complications. Mouth Neoplasms / diagnosis. Neoplasms, Second Primary. Papillomavirus Infections / complications


26. Sanclemente G, Herrera S, Tyring SK, Rady PL, Zuleta JJ, Correa LA, He Q, Wolff JC: Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia. J Eur Acad Dermatol Venereol; 2007 Sep;21(8):1054-60
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia.
  • OBJECTIVE: To evaluate the efficacy of 5% imiquimod in HIV-positive male patients with anogenital warts or anal intraepithelial neoplasia (AIN), and to elucidate whether human papillomavirus (HPV) type and viral load were important for clinical outcome and recurrences.
  • CONCLUSIONS: The assumption that visible perianal warts are benign lesions in HIV-positive patients has to be reevaluated since an important number of such lesions could correspond to low-grade anal disease, which in turn could progress to high-grade anal disease or cancer.
  • Further studies are needed to document its utility to prevent high-grade dysplasia and/or anal cancer.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Anus Diseases / drug therapy. Anus Neoplasms / drug therapy. Condylomata Acuminata / drug therapy. Genital Diseases, Male / drug therapy. Papillomavirus Infections / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Carcinoma in Situ / drug therapy. Carcinoma in Situ / virology. Humans. Male. Middle Aged. Papillomaviridae / classification. Polymerase Chain Reaction. Treatment Outcome. Viral Load


27. Roma AA, Goldblum JR, Fazio V, Yang B: Expression of 14-3-3sigma, p16 and p53 proteins in anal squamous intraepithelial neoplasm and squamous cell carcinoma. Int J Clin Exp Pathol; 2008;1(5):419-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of 14-3-3sigma, p16 and p53 proteins in anal squamous intraepithelial neoplasm and squamous cell carcinoma.
  • 14-3-3sigma is a p53-regulated G2/M inhibitor involved in numerous cellular signaling pathways related to cell cycle, DNA repair and apoptosis.
  • Recent studies have showed that 14-3-3sigma was silenced transcriptionally through promoter hypermethylation mainly in HPV-negative vulvar squamous cell carcinoma (SCC).
  • However, the expression of 14-3-3sigma protein has not yet been studied in anal SCC and its precursor, anal intraepithelial neoplasm (AIN).
  • Fourteen cases of invasive anal SCC were also included in the study, including 8 cases associated with bowenoid AIN and 6 cases associated with differentiated AIN.
  • Weak staining for 14-3-3sigma was seen in anal squamous hyperplasia.
  • In conclusion, two histopathologic types of AIN, bowenoid and differentiated, have distinct immunoprofiles for p16 and p53, which suggests dual molecular pathways during anal carcinogenesis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):429-41 [10716158.001]
  • [Cites] Oncogene. 2000 Nov 2;19(46):5298-302 [11077447.001]
  • [Cites] J Low Genit Tract Dis. 2007 Jan;11(1):46-7 [17194951.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):463-8 [16894294.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4353-7 [10969776.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6049-54 [10811911.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):3105-10 [16886641.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):795-801 [16819320.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):183-92 [16697662.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):225-34 [16697215.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):161 [16697214.001]
  • [Cites] Mol Cell Proteomics. 2005 Jun;4(6):785-95 [15778465.001]
  • [Cites] Histopathology. 2005 Jun;46(6):718-20 [15910611.001]
  • [Cites] J Low Genit Tract Dis. 2005 Apr;9(2):108-13 [15870532.001]
  • [Cites] Cell Res. 2005 Apr;15(4):228-36 [15857577.001]
  • [Cites] Pathol Int. 2005 Feb;55(2):77-82 [15693853.001]
  • [Cites] AIDS Read. 2005 Feb;15(2):79-82, 85-6, 88, 91 [15712398.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1477-83 [15619206.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1591-7 [15547695.001]
  • [Cites] Semin Cancer Biol. 1998;8(5):345-57 [10101800.001]
  • [Cites] Mol Cell. 1997 Dec;1(1):3-11 [9659898.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 16;86(22):1711-6 [7966400.001]
  • [Cites] Pathol Int. 2004 Oct;54(10):743-50 [15482563.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1131-8 [15292943.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jul;23(3):206-14 [15213596.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2687-93 [15102672.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):931-43 [14737123.001]
  • [Cites] Oncogene. 2002 Mar 14;21(12):1876-81 [11896620.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45193-200 [11577088.001]
  • [Cites] Int J Gynecol Pathol. 2001 Jan;20(1):16-30 [11192069.001]
  • [Cites] Br J Dermatol. 2007 Sep;157(3):523-30 [17573882.001]
  • (PMID = 18787619.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480570
  • [Keywords] NOTNLM ; 14-3-3σ / AIN / Anal intraepithelial neoplasm / Bowenoid / differentiated / p16 / p53 / simplex
  •  go-up   go-down


28. Brewer NT, Ng TW, McRee AL, Reiter PL: Men's beliefs about HPV-related disease. J Behav Med; 2010 Aug;33(4):274-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Men's beliefs about HPV-related disease.
  • While human papillomavirus (HPV) infection is associated with genital warts, anal cancer, and oral cancer, limited research has examined what men think causes these diseases.
  • We sought to examine knowledge and beliefs about HPV-related disease among gay and bisexual men, who are at high risk for HPV infection and HPV-related cancers, and compare them to heterosexual men.
  • Fewer than half of men knew that HPV can cause genital warts (41%), anal cancer (24%), and oral cancers (23%).
  • Overall, most men believed that sexual behavior causes genital warts (70%) and anal cancer (54%), and tobacco use causes oral cancer (89%).
  • Many men were unaware that HPV infection can cause genital warts, oral cancer, and anal cancer.

  • MedlinePlus Health Information. consumer health - Sexual Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sex Transm Dis. 2009 Jan;36(1):58-62 [18830138.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):3036-46 [18980286.001]
  • [Cites] Int J STD AIDS. 2009 Apr;20(4):290-1 [19304982.001]
  • [Cites] Obstet Gynecol Clin North Am. 2009 Mar;36(1):187-200 [19344856.001]
  • [Cites] Prev Med. 2009 May;48(5):411-4 [18996144.001]
  • [Cites] Am J Public Health. 2010 Jun;100(6):1123-9 [20395576.001]
  • [Cites] Sex Transm Infect. 2010 Jun;86(3):241-6 [19951936.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):189-93 [11144896.001]
  • [Cites] Nicotine Tob Res. 2003 Dec;5(6):821-6 [14668066.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] J Clin Microbiol. 1995 Aug;33(8):2058-63 [7559948.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] Pediatrics. 2005 Apr;115(4):845-51 [15805354.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):606-16 [15825185.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25 [16949997.001]
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1044-57 [16991079.001]
  • [Cites] J Med Screen. 2006;13(4):201-7 [17217610.001]
  • [Cites] Prev Med. 2007 Aug-Sep;45(2-3):130-4 [17707077.001]
  • [Cites] Sex Transm Dis. 2008 Apr;35(4):357-60 [18360316.001]
  • [Cites] J Womens Health (Larchmt). 2008 May;17(4):539-48 [18370586.001]
  • [Cites] J Adolesc Health. 2008 Oct;43(4 Suppl):S61-7 [18809147.001]
  • [Cites] Nicotine Tob Res. 2008 Oct;10(10):1559-70 [18946775.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):363-72 [19190161.001]
  • (PMID = 20162346.001).
  • [ISSN] 1573-3521
  • [Journal-full-title] Journal of behavioral medicine
  • [ISO-abbreviation] J Behav Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA057726; United States / NCI NIH HHS / CA / R25CA57726
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS578640; NLM/ PMC4018629
  •  go-up   go-down


29. Palefsky J: Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS; 2009 Jan;4(1):52-6
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus-related disease in people with HIV.
  • PURPOSE OF REVIEW: The incidence of human papillomavirus (HPV)-related cancers has increased among people with HIV infection compared with the general population.
  • This review will describe recent findings in HPV-associated cancer incidence since the introduction of antiretroviral therapy, HPV/disease prevalence at sites other than cervix and anus, and recent data on screening and treatment of anal intraepithelial neoplasia.
  • RECENT FINDINGS: Consistent with high prevalence of anogenital HPV infection, new data on cervical intraepithelial neoplasia and anal intraepithelial neoplasia in HIV-positive men and women show that the incidence of cervical cancer has not declined since the introduction of antiretroviral therapy and that the incidence of anal cancer is rising.
  • Treatment methods for anal intraepithelial neoplasia have been described and show reasonable efficacy.
  • SUMMARY: New data imply that the problem of HPV-related cancers will not decline among HIV-positive men and women in the antiretroviral therapy era, highlighting the need to perform studies to determine if screening and treatment of anal intraepithelial neoplasia will prevent development of anal cancer.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Mar 15;88(6):1464-9 [10717631.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):915-20 [15220697.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2078-83 [18273049.001]
  • [Cites] J Invest Dermatol. 2008 Sep;128(9):2316-24 [18385760.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2008 Sep;140(1):103-7 [18472205.001]
  • [Cites] J Oral Pathol Med. 2008 Oct;37(9):555-9 [18355174.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):143-50 [17354235.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):565-75 [17380365.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] Int J STD AIDS. 2007 Aug;18(8):538-42 [17686215.001]
  • [Cites] Br J Dermatol. 2007 Sep;157(3):523-30 [17573882.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61 [18156992.001]
  • [Cites] Sex Transm Dis. 2008 Feb;35(2):197-202 [18216727.001]
  • [Cites] Int J STD AIDS. 2008 Feb;19(2):118-20 [18334066.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 [18334711.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Curr HIV/AIDS Rep. 2008 May;5(2):78-85 [18510893.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] Int J STD AIDS. 2008 Jul;19(7):445-9 [18574114.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]
  • (PMID = 19339939.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA054053-08; United States / NCI NIH HHS / CA / R01 CA054053; United States / NCI NIH HHS / CA / R01 CA088739; United States / NCI NIH HHS / CA / R01 CA054053-08; United States / NCI NIH HHS / CA / R01 CA088739-03; United States / NCI NIH HHS / CA / CA088739-03
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 36
  • [Other-IDs] NLM/ NIHMS94538; NLM/ PMC2756707
  •  go-up   go-down


30. Panther LA, Schlecht HP, Dezube BJ: Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients. AIDS Read; 2005 Feb;15(2):79-82, 85-6, 88, 91
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients.
  • The incidence of human papillomavirus (HPV)-related anal squamous cell carcinoma is increasing.
  • It is likely that long-standing HIV-related immunosuppression plays a significant role in the pathogenesis of anal carcinoma; however, a direct HIV-HPV interaction has also been implicated.
  • Using cervical cancer prevention as a paradigm, anal Pap smear screening as part of routine HIV preventive care has been proposed to detect and treat precancerous anal lesions in the hope of decreasing anal cancer rates.
  • All HIV-positive patients with invasive cancer of the anal canal, particularly those with CD4+ cell counts greater than 200/microL and those receiving HAART, should be managed in the same manner as their HIV-negative counterparts.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. HIV Infections / epidemiology. Papillomaviridae / isolation & purification. Papillomavirus Infections / epidemiology. Precancerous Conditions / pathology


31. Bonnet F, Morlat P: [Cancer and HIV infection: any association?]. Rev Med Interne; 2006 Mar;27(3):227-35
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer and HIV infection: any association?].
  • PURPOSE: Morbidity and mortality related to neoplasia are increasing in HIV-infected patients.
  • CURRENT KNOWLEDGE AND KEY-POINTS: The incidence of AIDS opportunistic infections dramatically decreased since the introduction of highly active antiretroviral therapy (HAART).
  • Among AIDS-cancers, the incidences of Kaposi sarcoma and of cerebral lymphoma decreased in a same way than AIDS infections but the incidences of systemic non-Hodgkin lymphoma and of cervical cancer decreased less than the others and remain higher than in the general population.
  • The most recent and large studies have also shown a 1.7 to 3 fold increased risk of developing non-AIDS cancers in HIV-infected patients when compared to the general population without significant impact of HAART on incidence curves.
  • These malignancies include Hodgkin disease, lung, anal, head and neck cancers, hemopathies, and conjunctival cancers.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16337065.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 86
  •  go-up   go-down


32. Ambinder RF, Bhatia K, Martinez-Maza O, Mitsuyasu R: Cancer biomarkers in HIV patients. Curr Opin HIV AIDS; 2010 Nov;5(6):531-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer biomarkers in HIV patients.
  • PURPOSE OF REVIEW: In this review, we update investigations related to cancer biomarkers in HIV-infected populations.
  • RECENT FINDINGS: CD4 lymphocyte count is associated with primary central nervous system lymphoma (PCNSL), systemic non-Hodgkin's lymphoma (NHL) (except perhaps for Burkitt lymphoma), Kaposi's sarcoma, cervical cancer, and anal cancer.
  • HIV load is associated with Burkitt lymphoma and systemic NHL (but not PCNSL), with Kaposi's sarcoma and with anal cancer.
  • Cytokines and related molecules (IL10, sCD30) may identify patients at high risk for NHL.
  • SUMMARY: CD4 lymphocyte count, HIV load, germline genetic polymorphisms, cytokine and related molecules, and immunoglobulin light chains all show increasing promise as biomarkers of malignancy in HIV patients.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2000 Jan 28;14(2):133-40 [10708283.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):979-84 [10566552.001]
  • [Cites] Clin Immunol. 2003 Nov;109(2):119-29 [14597210.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1396-7; author reply 1397-8 [15494920.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1838-42 [10068655.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3561-4 [10446961.001]
  • [Cites] Clin Immunol. 1999 Sep;92(3):293-9 [10479534.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):760-4 [15721423.001]
  • [Cites] Tumour Biol. 2006;27(4):187-94 [16651853.001]
  • [Cites] J Clin Virol. 2006 Aug;36(4):258-63 [16762591.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Int J Infect Dis. 2007 Mar;11(2):172-8 [16931088.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] PLoS Med. 2007 Mar 27;4(3):e96 [17388662.001]
  • [Cites] J Clin Virol. 2008 Aug;42(4):433-6 [18455472.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):427-9 [19322036.001]
  • [Cites] PLoS One. 2009;4(4):e5360 [19390683.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2496-502 [19349542.001]
  • [Cites] Haematologica. 2009 Jun;94(6):875-80 [19336735.001]
  • [Cites] J Infect Dis. 2009 Jul 1;200(1):79-87 [19476437.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5737-42 [19336755.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2354; author reply 2354-5 [19745076.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2730-2 [19638620.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Dec;52(5):611-22 [19770804.001]
  • [Cites] Lancet Oncol. 2009 Dec;10(12):1152-9 [19818686.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):170-9 [19654554.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Feb;16(2):287-91 [19835968.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):773-9 [20048176.001]
  • [Cites] Leuk Lymphoma. 2010 Mar;51(3):497-506 [20038229.001]
  • [Cites] J Clin Oncol. 2010 Mar 20;28(9):1514-9 [20177022.001]
  • [Cites] AIDS. 2010 Apr 24;24(7):1025-33 [20299965.001]
  • [Cites] Cancer Causes Control. 2010 May;21(5):759-69 [20087644.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 May 1;54(1):78-84 [20418723.001]
  • [Cites] Sex Transm Dis. 2010 May;37(5):311-5 [20065890.001]
  • [Cites] J Natl Cancer Inst. 2010 Jun 2;102(11):784-92 [20442214.001]
  • [Cites] BMC Cancer. 2010;10:278 [20537184.001]
  • [Cites] Clin Infect Dis. 2010 Aug 1;51(3):342-9 [20572760.001]
  • [Cites] PLoS One. 2010;5(7):e11448 [20625427.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]
  • (PMID = 20978397.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA121947-05; United States / NCI NIH HHS / CA / CA096888-05S2; United States / NCI NIH HHS / CA / UO1 CA 121947; United States / NCI NIH HHS / CA / P50 CA096888-05S2; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / P50 CA096888
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS274983; NLM/ PMC3055562
  •  go-up   go-down


33. Palefsky JM: Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health; 2010 Apr;46(4 Suppl):S12-9
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus-related disease in men: not just a women's issue.
  • The most common cause of mortality related to human papillomavirus (HPV) infection is cervical cancer.
  • HPV is associated with a variety of cancers in men, including anal cancer and a subset of penile and oral cancers.
  • The incidence of anal and oral cancers related to HPV is increasing in the general population and is growing even faster among individuals who are immunocompromised because of human immunodeficiency virus (HIV) infection.
  • Likewise, anal HPV infection and anal intraepithelial neoplasia are very common throughout a wide range of ages in both HIV-negative and HIV-positive men who have sex with men.
  • Other HPV-related diseases of clinical importance in men include condylomata acuminata (genital warts) and recurrent respiratory papillomatosis.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Men's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Antivir Ther. 2004 Feb;9(1):13-22 [15040532.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] J Infect Dis. 2004 Aug 1;190(3):468-76 [15243918.001]
  • [Cites] Sex Transm Dis. 2004 Oct;31(10):601-7 [15388997.001]
  • [Cites] JAMA. 1982 Apr 9;247(14):1988-90 [7062503.001]
  • [Cites] Int J Cancer. 1989 Aug 15;44(2):199-203 [2547727.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] J Med Virol. 1991 Mar;33(3):159-64 [1652616.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2036-43 [18708396.001]
  • [Cites] J Infect Dis. 2008 Sep 15;198(6):827-35 [18657037.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2683-91 [18843010.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2883-91 [18980292.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):59-70 [19050387.001]
  • [Cites] J Infect Dis. 2009 Jan 1;199(1):7-13 [19086813.001]
  • [Cites] J Adolesc Health. 2009 Jan;44(1):33-40 [19101456.001]
  • [Cites] Int J Cancer. 2009 Mar 15;124(6):1251-7 [19089913.001]
  • [Cites] Clin Infect Dis. 2009 Mar 1;48(5):536-46 [19191636.001]
  • [Cites] World J Urol. 2009 Apr;27(2):141-50 [18607597.001]
  • [Cites] Obstet Gynecol Clin North Am. 2009 Mar;36(1):187-200 [19344856.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1710-6 [16030106.001]
  • [Cites] Clin Infect Dis. 2005 Sep 1;41(5):612-20 [16080082.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2550-6 [16284377.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):326-33 [16492924.001]
  • [Cites] Lancet. 2006 Apr 15;367(9518):1247-55 [16631880.001]
  • [Cites] N Engl J Med. 2006 Jun 22;354(25):2645-54 [16790697.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):715-7 [16916390.001]
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1044-57 [16991079.001]
  • [Cites] Int J Colorectal Dis. 2007 Jan;22(1):1-5 [16133005.001]
  • [Cites] Emerg Infect Dis. 2007 Jan;13(1):28-41 [17370513.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):143-50 [17354235.001]
  • [Cites] Pediatr Infect Dis J. 2007 Mar;26(3):201-9 [17484215.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1107-14 [17548671.001]
  • [Cites] Lancet. 2007 Jun 30;369(9580):2161-70 [17602732.001]
  • [Cites] J Infect Dis. 2007 Oct 15;196(8):1128-36 [17955430.001]
  • [Cites] Br J Cancer. 2007 Nov 5;97(9):1322-8 [17923869.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 [18334711.001]
  • [Cites] J Infect Dis. 2008 Apr 1;197(7):957-66 [18429348.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Emerg Infect Dis. 2008 Jun;14(6):888-94 [18507898.001]
  • [Cites] Sex Transm Infect. 2008 Jun;84(3):161-6 [18339658.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] Curr Opin Oncol. 2000 Jul;12(4):345-52 [10888420.001]
  • [Cites] Sex Transm Infect. 2000 Jun;76(3):162-8 [10961190.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):189-93 [11144896.001]
  • [Cites] Laryngoscope. 2001 Jan;111(1):57-69 [11192901.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]
  • [Cites] Br J Cancer. 2002 Mar 4;86(5):705-11 [11875730.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1105-12 [11948269.001]
  • [Cites] Anticancer Res. 2009 May;29(5):1467-74 [19443352.001]
  • [Cites] AIDS. 2009 Jun 1;23(9):1135-42 [19390418.001]
  • [Cites] BMJ. 2009;339:b3884 [19815582.001]
  • [Cites] MMWR CDC Surveill Summ. 1992 Apr 24;41(2):1-7 [1594012.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1666-9 [8348498.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Dec;121(12):1386-91 [7488368.001]
  • [Cites] Acta Derm Venereol. 1995 Nov;75(6):470-4 [8651027.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1060-7 [8683637.001]
  • [Cites] Int J STD AIDS. 1996 May-Jun;7(3):197-200 [8799782.001]
  • [Cites] J Infect Dis. 1997 Aug;176(2):353-61 [9237700.001]
  • [Cites] Sex Transm Dis. 1997 Nov;24(10):567-72 [9383844.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320-6 [9525432.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6):744-54 [15599852.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 [15734974.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):67-76 [15842614.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):896-905 [15956651.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):606-16 [15825185.001]
  • [Cites] J Am Acad Dermatol. 2002 Sep;47(3):351-7 [12196743.001]
  • [Cites] Sex Transm Infect. 2002 Jun;78(3):215-8 [12238658.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] J Infect Dis. 2003 Apr 1;187(7):1064-70 [12660920.001]
  • [Cites] Clin Infect Dis. 2003 Jun 1;36(11):1397-403 [12766834.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):3-13 [12807939.001]
  • [Cites] J Infect Dis. 2004 Feb 15;189(4):677-85 [14767822.001]
  • [Cites] Med Microbiol Immunol. 2004 Feb;193(1):35-44 [12838415.001]
  • [ErratumIn] J Adolesc Health. 2010 Jun;46(6):614
  • (PMID = 20307839.001).
  • [ISSN] 1879-1972
  • [Journal-full-title] The Journal of adolescent health : official publication of the Society for Adolescent Medicine
  • [ISO-abbreviation] J Adolesc Health
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA054053-10; United States / NCI NIH HHS / CA / R01 CA054053; United States / NCI NIH HHS / CA / CA088739-05; United States / NCI NIH HHS / CA / R01 CA088739; United States / NCI NIH HHS / CA / R01 CA088739-05; United States / NCI NIH HHS / CA / R01 CA054053-10
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 91
  • [Other-IDs] NLM/ NIHMS180665; NLM/ PMC2871537
  •  go-up   go-down


34. Colón-López V, Ortiz AP, Palefsky J: Burden of human papillomavirus infection and related comorbidities in men: implications for research, disease prevention and health promotion among Hispanic men. P R Health Sci J; 2010 Sep;29(3):232-40
MedlinePlus Health Information. consumer health - Hispanic American Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burden of human papillomavirus infection and related comorbidities in men: implications for research, disease prevention and health promotion among Hispanic men.
  • Over the last two decades, research has established a strong causal link between specific types of HPV infection and cancer, particularly cervical, anal, vulvar/vaginal, penile, and oropharyngeal cancer.
  • With the world-wide introduction of two new prophylactic vaccines against high-risk HPVs causing cervical cancer, and the recent FDA approval of the quadrivalent vaccine in preventing genital warts in men, there is an urgency to determine the burden of HPV in Hispanic populations before vaccine programs are implemented on a widespread basis.
  • This review article summarizes existing research on HPV infection and HPV-related morbidities in men, with a particular emphasis on Hispanic men in the United States and Puerto Rico.
  • (1) genital warts, (2) HPV and related cancers and (3) biobehavioral and psychosocial factors related to HPV infection and vaccination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Board Fam Med. 2009 Jan-Feb;22(1):34-42 [19124631.001]
  • [Cites] J Infect Dis. 2009 Feb 1;199(3):362-71 [19133808.001]
  • [Cites] Int J Cancer. 2009 Mar 15;124(6):1251-7 [19089913.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2009 Feb;135(2):180-8 [19221247.001]
  • [Cites] J Infect Dis. 2009 Apr 1;199(7):965-73 [19239366.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):52-6 [19339939.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1077-83 [19318438.001]
  • [Cites] J Infect Dis. 2009 May 1;199(9):1263-9 [19320589.001]
  • [Cites] J Dent Res. 2009 Apr;88(4):300-6 [19407148.001]
  • [Cites] BMC Cancer. 2009;9:129 [19400958.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2009 Jun 5;58(21):589-91 [19498337.001]
  • [Cites] Contraception. 2009 Aug;80(2):158-62 [19631791.001]
  • [Cites] J Pediatr Adolesc Gynecol. 2009 Aug;22(4):205-15 [19646665.001]
  • [Cites] Public Health Genomics. 2009;12(5-6):291-307 [19684442.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Ethn Health. 2009 Dec;14(6):607-24 [19953392.001]
  • [Cites] Int J Epidemiol. 2010 Feb;39(1):166-81 [20022926.001]
  • [Cites] Gynecol Oncol. 2010 May;117(2 Suppl):S15-9 [20138345.001]
  • [Cites] J Adolesc Health. 2010 Apr;46(4 Suppl):S12-9 [20307839.001]
  • [Cites] J Infect Dis. 2010 May 1;201(9):1340-3 [20350160.001]
  • [Cites] Sex Transm Dis. 2010 Jun;37(6):386-91 [20081557.001]
  • [Cites] Sex Transm Infect. 2010 Jun;86(3):241-6 [19951936.001]
  • [Cites] Lancet Oncol. 2010 Aug;11(8):781-9 [20451455.001]
  • [Cites] P R Health Sci J. 2010 Sep;29(3):241-9 [20799511.001]
  • [Cites] J Community Health. 2000 Feb;25(1):67-78 [10706210.001]
  • [Cites] Oral Oncol. 2000 Jan;36(1):106-15 [10889929.001]
  • [Cites] Int J STD AIDS. 2001 Apr;12(4):211-5 [11319969.001]
  • [Cites] Sex Transm Dis. 2001 May;28(5):277-80 [11354266.001]
  • [Cites] Br J Cancer. 2001 Jul 6;85(1):46-54 [11437401.001]
  • [Cites] Am J Public Health. 2002 Mar;92(3):378-81 [11867314.001]
  • [Cites] Br J Cancer. 2002 Mar 4;86(5):705-11 [11875730.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1105-12 [11948269.001]
  • [Cites] Sex Transm Infect. 2002 Jun;78(3):215-8 [12238658.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] J Infect Dis. 2003 Apr 1;187(7):1064-70 [12660920.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1772-83 [14652239.001]
  • [Cites] Perspect Sex Reprod Health. 2004 Jan-Feb;36(1):6-10 [14982671.001]
  • [Cites] Herpes. 2004 Apr;11(1):8-11 [15115631.001]
  • [Cites] Epidemiol Rev. 2004;26:22-35 [15234945.001]
  • [Cites] JAMA. 2004 Jul 14;292(2):171-9 [15249566.001]
  • [Cites] Head Neck. 2004 Sep;26(9):778-84 [15350023.001]
  • [Cites] Sex Transm Dis. 2004 Oct;31(10):601-7 [15388997.001]
  • [Cites] Semin Cancer Biol. 2004 Dec;14(6):453-71 [15489139.001]
  • [Cites] Int J Addict. 1990 Jun;25(6):665-91 [2265869.001]
  • [Cites] J Infect Dis. 1997 Aug;176(2):353-61 [9237700.001]
  • [Cites] Genitourin Med. 1997 Jun;73(3):174-80 [9306896.001]
  • [Cites] Cancer Causes Control. 1999 Feb;10(1):27-33 [10334639.001]
  • [Cites] J Infect Dis. 2005 Feb 1;191 Suppl 1:S42-54 [15627230.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Mar;99(3):311-5 [15716837.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):896-905 [15956651.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1710-6 [16030106.001]
  • [Cites] Int J STD AIDS. 2005 Oct;16(10):667-70 [16212712.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1934-9 [16708372.001]
  • [Cites] Braz J Otorhinolaryngol. 2006 Mar-Apr;72(2):272-82 [16951865.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25 [16949997.001]
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1044-57 [16991079.001]
  • [Cites] Sex Transm Dis. 2007 Jul;34(7):479-84 [17413536.001]
  • [Cites] Dis Markers. 2007;23(4):261-72 [17627061.001]
  • [Cites] Cir Cir. 2007 May-Jun;75(3):151-5 [17659164.001]
  • [Cites] Prev Med. 2007 Aug-Sep;45(2-3):107-14 [17628649.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1429-35 [17724670.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2 Suppl 1):S2-5 [17938014.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2 Suppl 1):S24-6 [17938015.001]
  • [Cites] Arch Med Res. 2008 Feb;39(2):189-97 [18164962.001]
  • [Cites] Sex Transm Dis. 2008 Apr;35(4):357-60 [18360316.001]
  • [Cites] Am J Obstet Gynecol. 2008 May;198(5):500.e1-7 [18455524.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] Vaccine. 2008 Aug 19;26 Suppl 10:K17-28 [18847554.001]
  • [Cites] Vaccine. 2008 Aug 19;26 Suppl 10:K53-61 [18847557.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2901-9 [18980273.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2883-91 [18980292.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2892-900 [18980293.001]
  • [Cites] Sex Transm Dis. 2009 Jan;36(1):58-62 [18830138.001]
  • (PMID = 20799510.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / R03 DA027939-01; United States / NCI NIH HHS / CA / 5R25CA094186-08; United States / NCI NIH HHS / SC / SC2 AI090922-01; United States / NCI NIH HHS / SC / 1 SC2 AI090922-01; United States / NCI NIH HHS / CA / R25 CA094186; United States / NCI NIH HHS / CA / U54 CA096297; United States / NIAID NIH HHS / AI / SC2 AI090922; United States / NIDA NIH HHS / DA / R03 DA027939; United States / NCRR NIH HHS / RR / G12 RR003051-21; United States / NCRR NIH HHS / RR / G12 RR003051; United States / PHS HHS / / R03 027939-01; United States / NIAID NIH HHS / AI / SC2 AI090922-01; United States / NCRR NIH HHS / RR / G12RR03051; United States / NCI NIH HHS / CA / R25 CA094186-08; United States / NIMHD NIH HHS / MD / G12 MD007600; United States / NCI NIH HHS / CA / U54 CA096297-05; United States / NCI NIH HHS / CA / U54CA96297
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Puerto Rico
  • [Number-of-references] 99
  • [Other-IDs] NLM/ NIHMS266486; NLM/ PMC3038604
  •  go-up   go-down


35. Stier EA, Baranoski AS: Human papillomavirus-related diseases in HIV-infected individuals. Curr Opin Oncol; 2008 Sep;20(5):541-6
HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus-related diseases in HIV-infected individuals.
  • RECENT FINDINGS: Studies assessing geographic variations in human papillomavirus types and prevalence in cervical dysplasia and cancer in HIV-infected women suggest that although human papillomavirus types 16 and 18 dominate, multiple other human papillomavirus types may play a role in carcinogenesis.
  • Anal dysplasia and cancer incidence continues to rise in the highly active antiretroviral therapy era; however, data on outcomes following therapy for anal dysplasia (infrared coagulator, high-resolution anoscopy-guided ablation) and anal cancer (chemoradiation and possibly intensity-modulated radiation therapy) have been encouraging.
  • Oral human papillomavirus may be associated with lower genital tract human papillomavirus infection and may have implications in the development of oropharyngeal cancer.
  • SUMMARY: As HIV-infected patients in the highly active antiretroviral therapy era continue to have high rates of cervical and anal cancer, it is important to continue screening efforts and treatment of preinvasive disease.
  • Treatment options for anal dysplasia and anal cancer in HIV-infected individuals are expanding and may lead to decreased morbidity and mortality.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):355-62 [16832413.001]
  • [Cites] Cancer Biol Ther. 2006 Jun;5(6):684-90 [16855377.001]
  • [Cites] AIDS. 2006 Nov 28;20(18):2337-44 [17117020.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] J Clin Microbiol. 2006 Dec;44(12):4479-85 [17021055.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Jan 1;44(1):61-5 [17075388.001]
  • [Cites] JAMA. 2007 Feb 28;297(8):813-9 [17327523.001]
  • [Cites] Int J STD AIDS. 2007 Feb;18(2):77-80 [17331275.001]
  • [Cites] J Low Genit Tract Dis. 2007 Apr;11(2):90-7 [17415113.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(2):CD005643 [17443606.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 May 1;45(1):9-19 [17356467.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):143-50 [17354235.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1480-3 [17437020.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1908-10 [17494923.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] J Med Virol. 2007 Jun;79(6):758-65 [17457908.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1626-32 [17684137.001]
  • [Cites] Br J Dermatol. 2007 Sep;157(3):523-30 [17573882.001]
  • [Cites] J Infect Dis. 2007 Sep 15;196(6):887-94 [17703420.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 Sep;21(8):1054-60 [17714124.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1933-41 [17721101.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1957-63 [17721103.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):446-51 [17762569.001]
  • [Cites] Am J Obstet Gynecol. 2007 Oct;197(4):346-55 [17904957.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2484-91 [17683070.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • [Cites] N Engl J Med. 2007 Oct 18;357(16):1579-88 [17942871.001]
  • [Cites] N Engl J Med. 2007 Oct 18;357(16):1589-97 [17942872.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):244-6 [17764116.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61 [18156992.001]
  • [Cites] J Clin Pathol. 2008 Jan;61(1):84-8 [17483251.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):73-81 [18066626.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):474-9 [18202423.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/63-70 [16950019.001]
  • [Cites] Exp Mol Pathol. 2006 Aug;81(1):42-7 [16878360.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):36-40 [16283561.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):423-8 [9459645.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):3-13 [12807939.001]
  • (PMID = 19106657.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / U01 CA121947-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  • [Other-IDs] NLM/ NIHMS126311; NLM/ PMC2757652
  •  go-up   go-down


36. McRee AL, Reiter PL, Chantala K, Brewer NT: Does framing human papillomavirus vaccine as preventing cancer in men increase vaccine acceptability? Cancer Epidemiol Biomarkers Prev; 2010 Aug;19(8):1937-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does framing human papillomavirus vaccine as preventing cancer in men increase vaccine acceptability?
  • We conducted an experiment to see whether framing HPV vaccination as also preventing cancer in men would increase men's vaccination willingness.
  • In the within-subjects experiment, men read four randomly ordered vignettes that described hypothetical vaccines that prevented either genital warts alone, or genital warts and either anal cancer, oral cancer, or penile cancer.
  • RESULTS: Although only 42% of men were willing to receive HPV vaccine when it was framed as preventing genital warts alone, 60% were willing to get it when it was framed as preventing cancer in addition to genital warts (P < 0.001).
  • The effect of outcome framing was the same for heterosexual and gay/bisexual men and for the three cancer types examined.
  • CONCLUSIONS: Men may be more accepting of HPV vaccine when it is framed as preventing cancer, regardless which of the three most common HPV-related cancers in men is described.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2010 AACR.
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1044-57 [16991079.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/1-10 [16949995.001]
  • [Cites] Health Psychol. 2007 Mar;26(2):136-45 [17385964.001]
  • [Cites] Prev Med. 2007 Aug-Sep;45(2-3):107-14 [17628649.001]
  • [Cites] Health Psychol. 2007 Nov;26(6):745-52 [18020847.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):115-8 [17952620.001]
  • [Cites] Ann Behav Med. 2008 Apr;35(2):221-9 [18347893.001]
  • [Cites] J Am Coll Health. 2008 Jul-Aug;57(1):23-32 [18682342.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1872-9 [18708374.001]
  • [Cites] J Adolesc Health. 2008 Oct;43(4 Suppl):S61-7 [18809147.001]
  • [Cites] Vaccine. 2008 Aug 19;26 Suppl 10:K17-28 [18847554.001]
  • [Cites] Sex Transm Dis. 2009 Jan;36(1):58-62 [18830138.001]
  • [Cites] J Am Board Fam Med. 2009 Jan-Feb;22(1):34-42 [19124631.001]
  • [Cites] J Womens Health (Larchmt). 2009 Feb;18(2):225-33 [19183094.001]
  • [Cites] J Behav Med. 2010 Aug;33(4):274-81 [20162346.001]
  • [Cites] Am J Mens Health. 2011 Jul;5(4):297-305 [20798149.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):363-72 [19190161.001]
  • [Cites] Sex Transm Infect. 2009 Apr;85(2):148-9 [19153110.001]
  • [Cites] Obstet Gynecol Clin North Am. 2009 Mar;36(1):187-200 [19344856.001]
  • [Cites] Psychol Bull. 1992 Jul;112(1):155-9 [19565683.001]
  • [Cites] Soc Sci Med. 2009 Aug;69(3):475-80 [19540642.001]
  • [Cites] J Adolesc Health. 2010 Feb;46(2):113-23 [20113917.001]
  • [Cites] Sex Transm Dis. 2010 Mar;37(3):197-203 [20118831.001]
  • [Cites] Prev Med. 2010 Apr;50(4):213-4 [20153358.001]
  • [Cites] Sex Transm Infect. 2010 Jun;86(3):241-6 [19951936.001]
  • [Cites] AIDS Patient Care STDS. 1999 Dec;13(12):717-30 [10743535.001]
  • [Cites] Health Commun. 2003;15(4):375-92 [14527864.001]
  • [Cites] J Pers Soc Psychol. 1986 Dec;51(6):1173-82 [3806354.001]
  • [Cites] Health Psychol. 1993 Jul;12(4):324-33 [8404807.001]
  • [Cites] Psychol Bull. 1997 Jan;121(1):3-19 [9000890.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Adolesc Health. 2005 Sep;37(3):179-86 [16109336.001]
  • [Cites] Pediatrics. 2006 May;117(5):1486-93 [16651301.001]
  • [Cites] MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24 [17380109.001]
  • (PMID = 20647398.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA057726-19; United States / NCI NIH HHS / CA / R25 CA057726; United States / NCI NIH HHS / CA / R25 CA057726-19; United States / NCI NIH HHS / CA / R25 CA57726
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Other-IDs] NLM/ NIHMS212838; NLM/ PMC2919615
  •  go-up   go-down


37. Selgrad M, Malfertheiner P, Fini L, Goel A, Boland CR, Ricciardiello L: The role of viral and bacterial pathogens in gastrointestinal cancer. J Cell Physiol; 2008 Aug;216(2):378-88
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of viral and bacterial pathogens in gastrointestinal cancer.
  • The association of Helicobacter pylori (H. pylori) with gastric cancer is thus far the best understood model to comprehend the causal relationship between a microbial pathogen and cancer in the human gastrointestinal tract.
  • Besides H. pylori, a variety of other pathogens are now being recognized as potential carcinogens in different settings of human cancer.
  • In the case of H. pylori and gastric cancer, as well as the human papillomavirus and anal cancer, the causal relationship between the infectious agent and the related cancer in the gastrointestinal tract has been clearly confirmed by epidemiological and experimental studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Lancet. 1971 Jun 19;1(7712):1257-60 [4104715.001]
  • [Cites] Science. 1973 Aug 17;181(4100):674-6 [4353360.001]
  • [Cites] Nature. 1978 Jul 20;274(5668):215-7 [210386.001]
  • [Cites] Science. 1978 Sep 29;201(4362):1246-9 [211583.001]
  • [Cites] Am J Clin Pathol. 1978 Jul;70(1):1-5 [696666.001]
  • [Cites] Am J Surg Pathol. 1979 Dec;3(6):491-500 [534386.001]
  • [Cites] Ann N Y Acad Sci. 1980;354:326-31 [6261650.001]
  • [Cites] Cell. 1985 Dec;43(3 Pt 2):831-40 [3000618.001]
  • [Cites] Mol Cell Biol. 1985 Aug;5(8):1969-76 [3837853.001]
  • [Cites] Acta Pathol Jpn. 1986 Jun;36(6):815-25 [3020865.001]
  • [Cites] Proc R Soc Lond B Biol Sci. 1987 Jun 22;231(1262):1-11 [2888116.001]
  • [Cites] Cancer Surv. 1987;6(1):39-54 [2825987.001]
  • [Cites] J Med Microbiol. 1988 Jun;26(2):93-9 [3385767.001]
  • [Cites] J Virol. 1989 Feb;63(2):863-72 [2536108.001]
  • [Cites] J Virol. 1990 Mar;64(3):1353-6 [2154613.001]
  • [Cites] Gut. 1990 Feb;31(2):134-8 [2311970.001]
  • [Cites] Science. 1990 Apr 6;248(4951):76-9 [2157286.001]
  • [Cites] JAMA. 1990 Dec 5;264(21):2724, 2727 [2232049.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Gut. 1991 Dec;32(12):1473-7 [1773951.001]
  • [Cites] Cancer. 1996 Apr 15;77(8 Suppl):1605-13 [8608551.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2463-7 [8653676.001]
  • [Cites] J Pathol. 1996 Feb;178(2):122-7 [8683376.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7352-7 [8692997.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4610-3 [8840972.001]
  • [Cites] Oncogene. 1996 Oct 17;13(8):1809-13 [8895528.001]
  • [Cites] Oncogene. 1999 Dec 13;18(53):7690-700 [10618709.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6124-31 [10626802.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1263-8 [10655519.001]
  • [Cites] J Exp Med. 2000 Feb 21;191(4):593-602 [10684851.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1497-500 [10688800.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):623-39 [10800981.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1031-8 [10833477.001]
  • [Cites] Blood. 2000 Jul 15;96(2):410-9 [10887100.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):981-5 [11008919.001]
  • [Cites] Gastroenterol Clin North Am. 2000 Sep;29(3):559-78 [11030073.001]
  • [Cites] Oncogene. 2000 Oct 5;19(42):4840-6 [11039901.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1191-202 [11054376.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1228-35 [11054380.001]
  • [Cites] Mol Pathol. 2000 Oct;53(5):255-61 [11091849.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] EMBO J. 2000 Dec 1;19(23):6361-70 [11101509.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14668-73 [11121067.001]
  • [Cites] J Virol. 2001 Feb;75(4):1996-2001 [11160700.001]
  • [Cites] Cell Microbiol. 2000 Apr;2(2):155-64 [11207572.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1934-40 [11280749.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2684-9 [11289148.001]
  • [Cites] Curr Top Microbiol Immunol. 2001;258:91-102 [11443869.001]
  • [Cites] Infect Immun. 2001 Aug;69(8):5080-7 [11447189.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):163-7 [9988266.001]
  • [Cites] Gastroenterology. 1999 Apr;116(4):823-30 [10092304.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7484-9 [10377441.001]
  • [Cites] Histopathology. 1999 Jun;34(6):502-9 [10383694.001]
  • [Cites] Carcinogenesis. 1999 Aug;20(8):1433-8 [10426788.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Front Biosci. 2006;11:2672-713 [16720343.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):1950-61 [16762618.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):1975-84 [16762620.001]
  • [Cites] Cell Microbiol. 2006 Jul;8(7):1188-98 [16819970.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1354-9 [16615110.001]
  • [Cites] Helicobacter. 2006 Oct;11 Suppl 1:32-5 [16925609.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):481-8 [16795066.001]
  • [Cites] Oncogene. 2006 Aug 28;25(38):5294-301 [16936750.001]
  • [Cites] Br J Cancer. 2006 Sep 18;95(6):744-51 [16940985.001]
  • [Cites] J Virol. 2007 Jan;81(2):1033-6 [17079300.001]
  • [Cites] Histopathology. 2007 Jan;50(1):113-30 [17204026.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):905-12 [17324405.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 May;133(5):287-96 [17393199.001]
  • [Cites] Cancer Sci. 2007 Jan;98(1):25-31 [17083566.001]
  • [Cites] Crit Rev Oncog. 2006 Dec;12(3-4):273-87 [17425506.001]
  • [Cites] Nat Rev Microbiol. 2007 Jun;5(6):441-52 [17505524.001]
  • [Cites] Gut. 2007 Jun;56(6):772-81 [17170018.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):659-72 [17681184.001]
  • [Cites] Acta Gastroenterol Latinoam. 2007 Jun;37(2):110-7 [17684942.001]
  • [Cites] J Cell Biochem. 2007 Oct 1;102(2):264-73 [17486575.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):2036-40 [17389608.001]
  • [Cites] Nature. 2007 Oct 18;449(7164):862-6 [17943123.001]
  • [Cites] Science. 2004 Apr 30;304(5671):734-6 [15118162.001]
  • [Cites] AIDS. 2004 Jul 23;18(11):1561-9 [15238774.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Oncogene. 2004 Jul 15;23(32):5459-67 [15133494.001]
  • [Cites] Dtsch Med Wochenschr. 2004 Aug 20;129(34-35):1821-6 [15314747.001]
  • [Cites] Nat Rev Cancer. 2004 Sep;4(9):688-94 [15343275.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6766-74 [15374995.001]
  • [Cites] Carcinogenesis. 2001 Nov;22(11):1737-46 [11698334.001]
  • [Cites] Int J Cancer. 2002 Jan 1;97(1):72-81 [11774246.001]
  • [Cites] Science. 2002 Jan 25;295(5555):683-6 [11743164.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):6775-8 [11788577.001]
  • [Cites] J Immunol. 2002 Mar 15;168(6):3033-41 [11884476.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):28-37 [11902583.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):244-65 [11919208.001]
  • [Cites] Mol Microbiol. 2002 Feb;43(4):971-80 [11929545.001]
  • [Cites] J Infect Dis. 2002 May 1;185(9):1229-37 [12001039.001]
  • [Cites] J Clin Pathol. 2002 Aug;55(8):587-90 [12147651.001]
  • [Cites] Hum Pathol. 2002 Jul;33(7):686-92 [12196918.001]
  • [Cites] J Clin Pathol. 2002 Oct;55(10):721-8 [12354793.001]
  • [Cites] N Engl J Med. 2002 Oct 10;347(15):1175-86 [12374879.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1645-51 [12444178.001]
  • [Cites] Virus Res. 2002 Nov;89(2):213-28 [12445661.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7093-101 [12460931.001]
  • [Cites] J Virol. 2003 Jan;77(2):1551-63 [12502868.001]
  • [Cites] J Infect Dis. 2003 Jan 15;187(2):334-7 [12552462.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3664-70 [12446738.001]
  • [Cites] Trends Microbiol. 2003 Mar;11(3):134-8 [12648945.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1608-14 [12670912.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1193-201 [12730860.001]
  • [Cites] Science. 2003 May 30;300(5624):1430-4 [12775840.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):57-65 [12807947.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1012-8 [12676782.001]
  • [Cites] Science. 2003 Aug 22;301(5636):1099-102 [12934009.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6517-23 [14528276.001]
  • [Cites] J Med Screen. 2003;10(3):148-56 [14561268.001]
  • [Cites] Lab Invest. 2003 Oct;83(10):1517-27 [14563953.001]
  • [Cites] Clin Microbiol Rev. 1992 Jan;5(1):49-73 [1310438.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 18;84(6):394-8 [1311392.001]
  • [Cites] J Clin Gastroenterol. 1996 Oct;23(3):207-10 [8899503.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):295-9 [8903469.001]
  • [Cites] J Virol. 1996 Dec;70(12):8653-9 [8970991.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):92-9 [8978347.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):7070-8 [9003782.001]
  • [Cites] J Pathol. 1996 Dec;180(4):378-82 [9014857.001]
  • [Cites] Cell. 1997 Feb 7;88(3):323-31 [9039259.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):808-11 [9041175.001]
  • [Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]
  • [Cites] Gut. 1997 Mar;40(3):297-301 [9135515.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Scand J Gastroenterol. 1997 May;32(5):465-8 [9175208.001]
  • [Cites] Blood. 1997 Jul 15;90(2):766-75 [9226177.001]
  • [Cites] J Cell Biochem. 1997 Nov 1;67(2):223-30 [9328827.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] EMBO J. 1997 Oct 15;16(20):6131-40 [9359753.001]
  • [Cites] Int J Cancer. 1997 Dec 10;73(6):786-9 [9399652.001]
  • [Cites] Science. 1998 Jan 16;279(5349):373-7 [9430586.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):423-8 [9459645.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] JAMA. 1998 May 20;279(19):1554-9 [9605900.001]
  • [Cites] Gastroenterology. 1998 Jun;114(6):1169-79 [9609753.001]
  • [Cites] Leukemia. 1998 Jun;12(6):937-41 [9639423.001]
  • [Cites] J Clin Invest. 1998 Oct 15;102(8):1506-14 [9788963.001]
  • [Cites] J Pathol. 1998 Aug;185(4):409-12 [9828840.001]
  • [Cites] Pathology. 1998 Nov;30(4):348-54 [9839308.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1910-7 [16344059.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):141-8 [16357845.001]
  • [Cites] J Pathol. 2006 Jan;208(2):233-48 [16362989.001]
  • [Cites] J Biochem Mol Biol. 2006 Jan 31;39(1):1-8 [16466631.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 15):2-8 [10566604.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14559-64 [10588744.001]
  • [Cites] Lancet. 1992 Mar 21;339(8795):745-6 [1347613.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):769-74 [1314023.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4442-6 [1316608.001]
  • [Cites] J Pathol. 1993 Feb;169(2):221-7 [8445487.001]
  • [Cites] Virus Res. 1993 Feb;27(2):133-45 [8384765.001]
  • [Cites] Infect Immun. 1993 May;61(5):1799-809 [8478069.001]
  • [Cites] Science. 1993 May 7;260(5109):812-6 [8484121.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5455-9 [8390666.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5791-5 [8516329.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9150-4 [8415670.001]
  • [Cites] Am J Pathol. 1993 Nov;143(5):1250-4 [8238241.001]
  • [Cites] Int J Cancer. 1993 Dec 2;55(6):891-903 [8253525.001]
  • [Cites] J Virol. 1994 Feb;68(2):787-96 [8289382.001]
  • [Cites] Science. 1994 Jul 1;265(5168):92-5 [8016657.001]
  • [Cites] Gastroenterology. 1994 Jul;107(1):128-36 [7912679.001]
  • [Cites] J Clin Pathol. 1994 May;47(5):436-9 [8027397.001]
  • [Cites] Oncogene. 1994 Oct;9(10):2943-50 [8084597.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):549-60 [7845680.001]
  • [Cites] Int J Cancer. 1995 Mar 16;60(6):820-2 [7896452.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241 [7715068.001]
  • [Cites] Am J Pathol. 1995 Jun;146(6):1355-67 [7778675.001]
  • [Cites] J Biol Chem. 1995 Jul 28;270(30):17771-7 [7629077.001]
  • [Cites] J Med Virol. 1995 Apr;45(4):435-8 [7666044.001]
  • [Cites] Infect Immun. 1995 Oct;63(10):4154-60 [7558333.001]
  • [Cites] AIDS. 1995 Nov;9(11):1255-62 [8561979.001]
  • [Cites] Blood. 1995 Dec 15;86(12):4587-93 [8541549.001]
  • [Cites] Hum Pathol. 1996 Jan;27(1):20-7 [8543306.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):952-9 [8622698.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):364-71 [12891537.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12778-83 [10535999.001]
  • [Cites] Gynecol Oncol. 1999 Sep;74(3):519-26 [10479524.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11519-24 [10500209.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15730-5 [15498875.001]
  • [Cites] Lancet. 1964 Mar 28;1(7335):702-3 [14107961.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Science. 2004 Nov 26;306(5701):1568-71 [15567866.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):1024-30; discussion 1031 [15585390.001]
  • [Cites] World J Gastroenterol. 2005 Feb 7;11(5):629-33 [15655811.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):516-27 [15630684.001]
  • [Cites] Gut. 2005 Mar;54(3):330-5 [15710978.001]
  • [Cites] J Obstet Gynaecol Res. 2005 Apr;31(2):178-84 [15771646.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 May;131(5):305-13 [15616827.001]
  • [Cites] Nat Rev Microbiol. 2005 Apr;3(4):320-32 [15759043.001]
  • [Cites] Lancet Oncol. 2005 Apr;6(4):204 [15830458.001]
  • [Cites] FEMS Immunol Med Microbiol. 2005 Jul 1;45(1):11-23 [15949928.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9300-5 [15972330.001]
  • [Cites] Am J Gastroenterol. 2005 Sep;100(9):2100-15 [16128957.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6370-8 [16155022.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2485-501 [16243519.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):35-46 [15965906.001]
  • [Cites] Brain Res Brain Res Rev. 2005 Dec 1;50(1):69-85 [15982744.001]
  • [Cites] J Cell Physiol. 2006 Feb;206(2):295-300 [15991250.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7256-62 [14612521.001]
  • [Cites] Gut. 2004 Jan;53(1):34-7 [14684573.001]
  • [Cites] Int J Gastrointest Cancer. 2003;33(2-3):165-70 [14716066.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Oncol Rep. 2004 Mar;11(3):647-54 [14767516.001]
  • [Cites] Acta Oncol. 2003;42(8):809-15 [14968941.001]
  • [Cites] Mol Pathol. 2001 Oct;54(5):331-7 [11577176.001]
  • [Cites] Gastroenterology. 2001 Oct;121(4):784-91 [11606491.001]
  • (PMID = 18338378.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098572; United States / NCI NIH HHS / CA / R01 CA72851; United States / NCI NIH HHS / CA / R01 CA072851-13; United States / NCI NIH HHS / CA / R01 CA98572; United States / NCI NIH HHS / CA / R01 CA072851; United States / NCI NIH HHS / CA / R01 CA098572-05; United States / NCI NIH HHS / CA / CA098572-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 220
  • [Other-IDs] NLM/ NIHMS187529; NLM/ PMC2855192
  •  go-up   go-down


38. Barbaro G, Barbarini G: HIV infection and cancer in the era of highly active antiretroviral therapy (Review). Oncol Rep; 2007 May;17(5):1121-6
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV infection and cancer in the era of highly active antiretroviral therapy (Review).
  • The majority of cancers affecting HIV-infected subjects are those established as acquired immunodeficiency syndrome (AIDS)-defining: Kaposi's sarcoma (KS), non-Hodgkin's lymphoma (NHL), and invasive cervical cancer (ICC).
  • However, other types of cancer, such as Hodgkin's disease (HD), anal cancer, lung cancer and testicular germ cell tumors appear to be more common among HIV-infected subjects compared to the general population.
  • While not classified as AIDS-defining, these malignancies have been referred to as AIDS-associated malignancies.
  • The mechanisms by which depressed immunity could increase the risk for cancer are unclear, except for in KS and most subtypes of NHL, where it is strictly associated with a low CD4 count.
  • Studies of the effect of highly active antiretroviral therapy (HAART) on the incidence and progression of HIV/AIDS-associated cancers provided contrasting data.
  • While a significant decrease in the incidence of KS has been observed, HAART has not had a significant impact on NHL incidence, particularly systemic NHL, or on ICC, HD, anal cancers and other non-AIDS-defining cancers.
  • Regardless of whether these cancers are directly related to HIV-induced immunodeficiency, treating cancer in HIV-infected patients remains a challenge because of drug interactions, compounded side effects, and the potential effect of chemotherapy on CD4 count and HIV-1 viral load.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17390054.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 44
  •  go-up   go-down


39. Gillison ML: Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr Opin Oncol; 2009 Sep;21(5):439-44
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection.
  • PURPOSE OF REVIEW: Oral human papillomavirus (HPV) infection is the principal cause of a distinct form of oropharyngeal cancer (OPCA) that has been rising in incidence in the United States since 1973, particularly among young men.
  • RECENT FINDINGS: Incidence rates for HPV-related OPCA increased with age and were strongly influenced by year of birth in the United States (cohort effect).
  • Persons with HIV/AIDS are at increased risk ( approximately two to six-fold) for OPCA relative to the general population.
  • Consistent with a viral attribution, however, is the apparent increase in risk of OPCA with severity of AIDS-related immunosuppression.
  • Analogous to other HPV-related cancers (e.g. cervical and anal cancer), trends over time do not appear to be influenced by highly active antiretroviral (HAART) therapy.
  • SUMMARY: Healthcare providers may encounter HPV-related OPCA more frequently among individuals with HIV/AIDS as this population ages and due to the strong birth cohort effects observed in the general population.
  • However, there is no evidence in support of different incidence trends over time among persons with and without HIV/AIDS.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19587593.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


40. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S, Swiss HIV Cohort: Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst; 2005 Mar 16;97(6):425-32
MedlinePlus Health Information. consumer health - Smoking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
  • BACKGROUND: Persons infected with human immunodeficiency virus (HIV) have an increased risk for several cancers, but the influences of behavioral risk factors, such as smoking and intravenous drug use, and highly active antiretroviral therapy (HAART) on cancer risk are not clear.
  • METHODS: Patient records were linked between the Swiss HIV Cohort Study and Swiss cantonal cancer registries.
  • Relative risks for cancer compared with those for the general population were determined by estimating cancer registry-, sex-, age-, and period-standardized incidence ratios (SIRs).
  • Statistically significantly elevated SIRs were also observed for anal cancer (SIR = 33.4, 95% CI = 10.5 to 78.6); Hodgkin lymphoma (SIR = 17.3, 95% CI = 10.2 to 27.4); cancers of the cervix (SIR = 8.0, 95% CI = 2.9 to 17.4); liver (SIR = 7.0, 95% CI = 2.2 to 16.5); lip, mouth, and pharynx (SIR = 4.1, 95% CI = 2.1 to 7.4); trachea, lung, and bronchus (SIR = 3.2, 95% CI = 1.7 to 5.4); and skin, nonmelanomatous (SIR = 3.2, 95% CI = 2.2 to 4.5).
  • No clear impact of HAART on SIRs emerged for cervical cancer or non-acquired immunodeficiency syndrome-defining cancers.
  • [MeSH-minor] Adult. Aged. Cohort Studies. Confounding Factors (Epidemiology). Female. Humans. Incidence. Lymphocyte Count. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / virology. Male. Medical Record Linkage. Middle Aged. Odds Ratio. Papillomaviridae. Prospective Studies. Registries. Research Design. Risk Assessment. Risk Factors. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / virology. Switzerland / epidemiology. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2005 Mar 16;97(6):407-9 [15769998.001]
  • (PMID = 15770006.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


41. Buonaguro L, Petrizzo A, Tornesello M, Napolitano M, Martorelli D, Castello G, Beneduce G, De Renzo A, Perrella O, Romagnoli L, Sousa V, De Re V, Dolcetti R, Buonaguro FM: Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders. J Transl Med; 2010;8:18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders.
  • Hepatitis C virus (HCV) is one of the major risk factors for chronic hepatitis, which may progress to cirrhosis and hepatocellular carcinoma, as well as for type II mixed cryoglobulinemia (MC), which may further evolve into an overt B-cell non-Hodgkin's lymphoma (NHL).

  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):211-6 [10861476.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3578-84 [11071657.001]
  • [Cites] J Clin Lab Anal. 2002;16(1):40-6 [11835530.001]
  • [Cites] Ann Intern Med. 2002 Oct 1;137(7):571-80 [12353944.001]
  • [Cites] Turk J Gastroenterol. 2003 Mar;14(1):7-11 [14593531.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4262-7 [14999097.001]
  • [Cites] Cell Res. 2004 Jun;14(3):251-6 [15225419.001]
  • [Cites] J Exp Med. 1989 Sep 1;170(3):827-45 [2504877.001]
  • [Cites] Ann Intern Med. 1992 Oct 1;117(7):573-7 [1326246.001]
  • [Cites] J Exp Med. 1993 Sep 1;178(3):1041-8 [8102388.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3701-4 [8260706.001]
  • [Cites] J Exp Med. 1994 Apr 1;179(4):1109-18 [8145033.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):211-22 [7516408.001]
  • [Cites] J Intern Med. 1994 Jul;236(1):31-6 [8021570.001]
  • [Cites] Br J Haematol. 1994 Oct;88(2):392-4 [7803287.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4638-45 [8977256.001]
  • [Cites] J Hepatol. 1997 Mar;26(3):471-8 [9075651.001]
  • [Cites] Clin Rev Allergy Immunol. 1997 Spring;15(1):97-119 [9209804.001]
  • [Cites] Ann Intern Med. 1997 Sep 15;127(6):423-8 [9312998.001]
  • [Cites] Mediators Inflamm. 1998;7(4):295-7 [9792341.001]
  • [Cites] Science. 1998 Oct 30;282(5390):938-41 [9794763.001]
  • [Cites] J Immunol. 1999 Aug 1;163(3):1666-73 [10415073.001]
  • [Cites] J Hepatol. 2005 Jan;42(1):61-7 [15629508.001]
  • [Cites] J Virol. 2005 Mar;79(5):3052-62 [15709025.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2005 May;17(5):477-83 [15827436.001]
  • [Cites] J Infect Dis. 2005 Aug 1;192(3):497-503 [15995965.001]
  • [Cites] J Virol. 2006 Sep;80(18):9134-43 [16940524.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):1205-7 [17383452.001]
  • [Cites] World J Gastroenterol. 2007 May 7;13(17):2467-78 [17552031.001]
  • [Cites] Clin Vaccine Immunol. 2007 Sep;14(9):1127-37 [17634507.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1344-56 [17942751.001]
  • [Cites] BMC Bioinformatics. 2008;9 Suppl 2:S5 [18387207.001]
  • [Cites] Autoimmun Rev. 2008 Jun;7(6):468-72 [18558364.001]
  • [Cites] Clin Exp Rheumatol. 2008 Jan-Feb;26(1 Suppl 48):S39-47 [18570753.001]
  • [Cites] J Virol. 2009 Jan;83(1):304-13 [18945779.001]
  • [Cites] Nat Immunol. 2009 Jan;10(1):116-25 [19029902.001]
  • [Cites] J Exp Med. 2008 Dec 22;205(13):3119-31 [19047440.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Aug;7(8):900-5 [19362606.001]
  • [Cites] AIDS Res Hum Retroviruses. 2009 Aug;25(8):819-22 [19630502.001]
  • [Cites] Nat Rev Cancer. 2009 Sep;9(9):675-81 [19701243.001]
  • [Cites] FEBS Lett. 2009 Sep 17;583(18):3004-8 [19665024.001]
  • [Cites] Ann N Y Acad Sci. 2009 Sep;1173:152-60 [19758144.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):223-31 [7516409.001]
  • (PMID = 20170491.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cytokines; 0 / Immunoglobulin Idiotypes; 0 / Immunoglobulin Variable Region; 0 / Receptors, Antigen, B-Cell; 0 / Viral Vaccines
  • [Other-IDs] NLM/ PMC2839974
  •  go-up   go-down


42. Clifford GM, Franceschi S: Cancer risk in HIV-infected persons: influence of CD4(+) count. Future Oncol; 2009 Jun;5(5):669-78
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer risk in HIV-infected persons: influence of CD4(+) count.
  • Whereas Kaposi sarcoma and non-Hodgkin lymphoma were recognised as AIDS-defining illnesses early in the HIV epidemic, the influence of declining CD4(+) count on other infection-related cancers has taken longer to establish, undoubtedly because the association is weaker and the dose-response relationship is less steep.
  • However, following improved survival made possible by combined antiretroviral therapy, declining CD4(+) count starts showing an impact on the natural history of various carcinogenic infections and on the risk for an increasingly wide range of cancers, including Hodgkin lymphoma, cervical, anal and liver cancers.

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19519206.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 91
  •  go-up   go-down


43. Pollicita M, Muscoli C, Sgura A, Biasin A, Granato T, Masuelli L, Mollace V, Tanzarella C, Del Duca C, Rodinò P, Perno CF, Aquaro S: Apoptosis and telomeres shortening related to HIV-1 induced oxidative stress in an astrocytoma cell line. BMC Neurosci; 2009;10:51
Hazardous Substances Data Bank. N-ACETYLCYSTEINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis and telomeres shortening related to HIV-1 induced oxidative stress in an astrocytoma cell line.

  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Neurol. 1999 Aug;12(4):377-81 [10555824.001]
  • [Cites] Exp Gerontol. 2007 Nov;42(11):1039-42 [17869047.001]
  • [Cites] Lab Invest. 2000 Nov;80(11):1739-47 [11092534.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):417-24 [11133373.001]
  • [Cites] J Neurosci Res. 2001 Jan 1;63(1):1-9 [11169608.001]
  • [Cites] Ann Neurol. 2001 Jun;49(6):745-52 [11409426.001]
  • [Cites] Trends Neurosci. 2001 Jul;24(7):411-6 [11410272.001]
  • [Cites] Free Radic Biol Med. 2001 Sep 15;31(6):824-31 [11557321.001]
  • [Cites] J Leukoc Biol. 2002 Jan;71(1):65-72 [11781381.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):532-40 [11850778.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):598-610 [11850785.001]
  • [Cites] J Am Chem Soc. 2002 Feb 27;124(8):1625-31 [11853436.001]
  • [Cites] Free Radic Biol Med. 2002 Jul 15;33(2):192-200 [12106815.001]
  • [Cites] Hum Mol Genet. 2003 Feb 1;12(3):227-32 [12554677.001]
  • [Cites] BMC Neurosci. 2002 Sep 16;3:13 [12234380.001]
  • [Cites] J Infect Dis. 2003 Jul 15;188(2):232-8 [12854078.001]
  • [Cites] Lancet. 2003 Sep 20;362(9388):983-8 [14511933.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1019:278-84 [15247029.001]
  • [Cites] Neurology. 2004 Aug 24;63(4):626-30 [15326233.001]
  • [Cites] Cell. 2004 Oct 29;119(3):355-68 [15507207.001]
  • [Cites] Cell. 1989 Nov 3;59(3):521-9 [2805070.001]
  • [Cites] Lancet. 1989 Dec 2;2(8675):1294-8 [2574255.001]
  • [Cites] Methods Enzymol. 1994;233:594-601 [7912408.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1121-30 [7747806.001]
  • [Cites] Exp Cell Res. 1995 Sep;220(1):186-93 [7664835.001]
  • [Cites] Neurology. 1995 Sep;45(9):1678-83 [7675226.001]
  • [Cites] Stem Cells. 1996 Mar;14(2):239-48 [8991544.001]
  • [Cites] AIDS Res Hum Retroviruses. 1996 Sep 20;12(14):1373-81 [8891117.001]
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):1979-90 [8903316.001]
  • [Cites] Cancer Surv. 1996;28:197-216 [8977036.001]
  • [Cites] J Biol Chem. 1997 Jan 31;272(5):2700-8 [9006907.001]
  • [Cites] Free Radic Biol Med. 1997;22(5):775-85 [9119245.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1967-72 [9050888.001]
  • [Cites] Hum Mol Genet. 1997 Jun;6(6):905-8 [9175737.001]
  • [Cites] J Leukoc Biol. 1997 Jul;62(1):54-9 [9225993.001]
  • [Cites] Exp Cell Res. 1998 Feb 25;239(1):152-60 [9511733.001]
  • [Cites] Nature. 1998 Apr 9;392(6676):569-74 [9560153.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Mar;57(3):257-67 [9600218.001]
  • [Cites] Free Radic Biol Med. 1998 Apr;24(6):885-93 [9607597.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1011-9 [9920850.001]
  • [Cites] J Med Primatol. 1999 Feb;28(1):1-10 [10372535.001]
  • [Cites] FEBS Lett. 1999 Jun 25;453(3):365-8 [10405177.001]
  • [Cites] J Neuroimmunol. 2004 Dec;157(1-2):176-84 [15579295.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Anal Biochem. 1980 Jul 15;106(1):55-62 [7416469.001]
  • [Cites] Am J Pathol. 1980 Nov;101(2):331-44 [7435541.001]
  • [Cites] Science. 1988 Feb 5;239(4840):586-92 [3277272.001]
  • [Cites] J Investig Dermatol Symp Proc. 2005 Nov;10(2):89-94 [16358816.001]
  • [Cites] Biochem J. 2007 Jan 1;401(1):1-11 [17150040.001]
  • [Cites] J Med Virol. 2007 May;79(5):639-46 [17387751.001]
  • [Cites] Virology. 2007 Jul 5;363(2):462-72 [17336361.001]
  • [Cites] Neurochem Int. 2000 Mar;36(3):185-91 [10676851.001]
  • (PMID = 19463156.001).
  • [ISSN] 1471-2202
  • [Journal-full-title] BMC neuroscience
  • [ISO-abbreviation] BMC Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; GAN16C9B8O / Glutathione; ULW86O013H / Glutathione Disulfide; WYQ7N0BPYC / Acetylcysteine
  • [Other-IDs] NLM/ PMC2694812
  •  go-up   go-down


44. Dhir AA, Sawant SP: Malignancies in HIV: the Indian scenario. Curr Opin Oncol; 2008 Sep;20(5):517-21
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: India has the second largest number of HIV/AIDS patients in the world; however, studies done in the area of HIV-related malignancies are few.
  • With the availability of highly active antiretroviral therapy and treatment and prevention of opportunistic infections, an increase in life expectancy of HIV-infected individuals and an increase in HIV-related malignancies is expected.
  • The purpose of this review is to put forth the Indian scenario of HIV-related malignancies.
  • RECENT FINDINGS: About 2.5 million Indians have HIV/AIDS.
  • Non-Hodgkin's lymphoma and cervical cancer were found to occur in a higher proportion among the HIV-infected individuals in India as compared with non-HIV-infected individuals.
  • The incidence of AIDS-related primary central nervous system lymphoma is low in India.
  • Amongst the non-AIDS defining cancers anal cancer, testicular cancer, Hodgkin's disease, colon cancer and certain head and neck cancer sites in men and vaginal cancers among women were found to occur more frequently.
  • As India is a large country and geographically and culturally diverse, large-scale studies need to be done linking the regional cancer centres with the AIDS centres across the country to evaluate the exact burden of HIV-related malignancies.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / etiology. Neoplasms / etiology

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106653.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


45. Ho-Yen C, Chang F, van der Walt J, Lucas S: Gastrointestinal malignancies in HIV-infected or immunosuppressed patients: pathologic features and review of the literature. Adv Anat Pathol; 2007 Nov;14(6):431-43
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The gastrointestinal (GI) tract is a common internal organ to be involved by human immunodeficiency virus (HIV)-related malignancies.
  • It is the second most common site for Kaposi sarcoma after skin, and the commonest visceral site, for Kaposi sarcoma in AIDS patients.
  • GI lymphomas have been documented in approximately 25% of AIDS patients with systemic lymphomas.
  • Moreover, GI involvement of AIDS-lymphoma has been associated with poor prognosis and short survival.
  • Several other malignancies that occur in the GI tract are also closely related to HIV-infected or immunosuppressed individuals; these include posttransplant lymphoproliferative disorder, Epstein-Barr virus-associated smooth muscle tumors, anal precancerous lesions, and squamous cell carcinoma.
  • As a result of active antiretroviral therapy, patients infected with HIV are living longer and are consequently at increased risk for development of cancer.
  • Therefore, it is possible that the number of AIDS-associated malignancies will rise and the pattern of tumors may change in the future.
  • In this paper, the clinicopathologic features of GI malignancies associated with AIDS patients are reviewed and the differential diagnosis with other mimic lesions is discussed.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / pathology. Gastrointestinal Neoplasms / pathology. Immunocompromised Host. Immunosuppression. Lymphoma, AIDS-Related / pathology. Sarcoma, Kaposi / pathology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18049132.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 103
  •  go-up   go-down


46. Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM: Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis; 2010 Oct 15;202(8):1246-53
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Human immunodeficiency virus type 1 (HIV-1)-infected men are at increased risk for anal cancer.
  • Human papillomavirus (HPV) vaccination may prevent anal cancer caused by vaccine types.
  • METHODS: AIDS Malignancy Consortium Protocol 052 is a single-arm, open-label, multicenter clinical trial to assess the safety and immunogenicity of the quadrivalent HPV (types 6, 11, 16, and 18) vaccine in HIV-1-infected men.
  • Men with high-grade anal intraepithelial neoplasia or anal cancer by history or by screening cytology or histology were excluded.
  • The primary end points were seroconversion to vaccine types at week 28, in men who were seronegative and without anal infection with the relevant HPV type at entry, and grade 3 or higher adverse events related to vaccination.

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - HIV InSite .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J STD AIDS. 2009 Sep;20(9):595-600 [19710329.001]
  • [Cites] Lancet. 2009 Jun 6;373(9679):1949-57 [19493565.001]
  • [Cites] Clin Diagn Lab Immunol. 2003 Jan;10(1):108-15 [12522048.001]
  • [Cites] BMC Infect Dis. 2003 Apr 30;3:6 [12723991.001]
  • [Cites] Am J Obstet Gynecol. 1984 Aug 15;149(8):815-23 [6205589.001]
  • [Cites] Am J Pathol. 1992 Jun;140(6):1345-55 [1318640.001]
  • [Cites] J Clin Microbiol. 1992 Oct;30(10):2539-43 [1328278.001]
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):919-28 [9269808.001]
  • [Cites] J Infect Dis. 1997 Sep;176(3):625-31 [9291307.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] Clin Diagn Lab Immunol. 2005 Aug;12(8):959-69 [16085914.001]
  • [Cites] Clin Infect Dis. 2005 Oct 1;41(7):1045-8 [16142673.001]
  • [Cites] Vaccine. 2006 Jan 16;24(3):272-9 [16139398.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • (PMID = 20812850.001).
  • [ISSN] 1537-6613
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00513526
  • [Grant] United States / NCI NIH HHS / CA / U01CA121947-01; United States / NCRR NIH HHS / RR / UL1 RR024996; United States / NCRR NIH HHS / RR / UL1 RR024996-01; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCRR NIH HHS / RR / M01 RR000865-26; United States / NCRR NIH HHS / RR / UL1RR024996; United States / NIAID NIH HHS / AI / K23 AI055038; United States / NCRR NIH HHS / RR / UL1 RR024131; United States / NCI NIH HHS / CA / U01 CA121947-01; United States / NIAID NIH HHS / AI / K23 AI 55038; United States / NIAID NIH HHS / AI / K23 AI055038-01; United States / NCI NIH HHS / CA / CA121947-01; United States / NCRR NIH HHS / RR / UL1 RR024131-01; United States / NCRR NIH HHS / RR / M01-RR00865; United States / NCI NIH HHS / CA / U01 CA121947; United States / NIAID NIH HHS / AI / AI055038-01
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; 0 / Papillomavirus Vaccines
  • [Other-IDs] NLM/ NIHMS285476; NLM/ PMC3118428
  •  go-up   go-down


47. van Leeuwen MT, Vajdic CM, Middleton MG, McDonald AM, Law M, Kaldor JM, Grulich AE: Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. AIDS; 2009 Oct 23;23(16):2183-90
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe changes in cancer incidence in people with HIV in Australia since the introduction of highly active antiretroviral therapy (HAART).
  • DESIGN: Population-based, retrospective cohort study of people with HIV (n = 20 232) using data linkage between national registers of HIV/AIDS and cancer in 1982-2004.
  • METHODS: Age-adjusted and sex-adjusted incidence rate ratios with 95% confidence intervals were calculated to compare site-specific cancer incidence during the early (1996-1999) and late (2000-2004) HAART periods with that prior to HAART (1982-1995).
  • Incidence of anal cancer was unchanged (Ptrend = 0.451) and remained raised more than 30-fold.
  • Incidence declined significantly for melanoma (Ptrend = 0.041) and prostate cancer (Ptrend = 0.026), and, during the late-HAART period, was lower than in the general population for both cancers.
  • Incidence of colorectal cancer was consistently lower than in the general population.
  • Incidence of anal cancer has remained stable, and it is now the third most common cancer in HIV-infected Australians.
  • Reasons for the reduced incidence of colorectal and prostate cancer, and more recently of melanoma, are unclear.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Melanoma Res. 2009 Apr;19(2):63-8 [19194340.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Haematologica. 2009 Jun;94(6):875-80 [19336735.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5737-42 [19336755.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2297-303 [19622722.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] AIDS. 2001 Mar 30;15(5):629-33 [11317001.001]
  • [Cites] Am J Epidemiol. 2002 Jan 15;155(2):153-8 [11790679.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5230-5 [12234989.001]
  • [Cites] Sex Health. 2008 Jun;5(2):141-54 [18588779.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):800-4 [18665172.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] Circulation. 2009 Feb 17;119(6):770-2 [19221228.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):321-2 [19350698.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2627-36 [15197806.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] AIDS Patient Care STDS. 2005 Oct;19(10):655-71 [16232050.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):463-8 [16894294.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):401-4 [17337646.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • (PMID = 19734774.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI069907; United States / NIAID NIH HHS / AI / U01 AI069907-03; United States / NIAID NIH HHS / AI / U01AI069907
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS199813; NLM/ PMC2873230
  •  go-up   go-down


48. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, Klein D, Quesenberry CP Jr, Towner WJ, Abrams DI: HIV infection and the risk of cancers with and without a known infectious cause. AIDS; 2009 Nov 13;23(17):2337-45
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Adult HIV-infected and matched HIV-uninfected members of Kaiser Permanente followed between 1996 and 2007 for incident AIDS-defining cancers (ADCs), infection-related non-AIDS-defining cancers (NADCs; anal squamous cell, vagina/vulva, Hodgkin's lymphoma, penis, liver, human papillomavirus-related oral cavity/pharynx, stomach) and infection-unrelated NADC (all other NADCs).
  • HIV-infected persons experienced 552 ADC, 221 infection-related NADC, and 388 infection-unrelated NADC.
  • HIV-uninfected persons experienced 179 ADC, 284 infection-related NADC, and 3418 infection-unrelated NADC.
  • The rate ratio for infection-related NADC was 9.2 (95% CI: 7.7-11.1), also with decreases in the rate ratio over time (P < 0.001).
  • These results were largely influenced by anal squamous cell cancer and Hodgkin's lymphoma.
  • Among infection-unrelated NADCs, other anal, skin, other head and neck, and lung cancer rates were higher and prostate cancer rates lower in HIV-infected persons.
  • Among all infection-unrelated NADCs, the rate ratio decreased over time only for lung cancer (P = 0.007).

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prog Exp Tumor Res. 1970;13:1-27 [4921480.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] AIDS. 1998 Aug 20;12(12):1459-64 [9727566.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 3;91(3):226-36 [10037100.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] AIDS. 2009 Jan 28;23(3):385-93 [19114864.001]
  • [Cites] HIV Clin Trials. 2009 May-Jun;10(3):153-9 [19632954.001]
  • [Cites] J Hepatol. 2004 Jul;41(1):156-66 [15246224.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):753-7 [11745473.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] AIDS. 2002 May 3;16(7):993-1001 [11953465.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Clin Infect Dis. 2002 Oct 1;35(7):873-9 [12228825.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1383-8 [16549832.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] AIDS. 2007 Sep 12;21(14):1957-63 [17721103.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):446-51 [17762569.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(14):2117-23 [17764927.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):612-9 [18235120.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] Antivir Ther. 2008;13(3):455-60 [18572759.001]
  • [Cites] Curr HIV/AIDS Rep. 2008 Aug;5(3):140-9 [18627663.001]
  • [Cites] N Engl J Med. 1998 Apr 2;338(14):948-54 [9521982.001]
  • (PMID = 19741479.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / R01 AA016893; United States / NIAID NIH HHS / AI / K01 AI071725; United States / NIAID NIH HHS / AI / U01 AI069918-04; United States / NIAID NIH HHS / AI / K01 AI071725-03; United States / NIAID NIH HHS / AI / AI069918-04; United States / NIAID NIH HHS / AI / U01-AI069918; United States / NIAID NIH HHS / AI / K01AI071725; United States / NIAID NIH HHS / AI / AI071725-03; United States / NIAID NIH HHS / AI / U01 AI069918
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS198381; NLM/ PMC2863991
  •  go-up   go-down


49. Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, Ries LA, Fraumeni JF Jr: Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol; 2010 Nov 20;28(33):4935-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: We evaluated second cancer and leukemia risks among 43,145 1-year survivors of CLL/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), or follicular lymphoma (FL) from 11 Surveillance, Epidemiology, and End Results (SEER) population-based registries during 1992 to 2006.
  • RESULTS: Among patients without HIV/AIDS-related lymphoma, lung cancer risks were significantly elevated after CLL/SLL and FL but not after DLBCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL = 1.28, DLBCL = 1.00; Poisson regression P for difference among subtypes, P(Diff) = .001).
  • Patients with HIV/AIDS-related lymphoma (n = 932) were predominantly diagnosed with DLBCL and had significantly and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 138.90).

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):159-66 [15970927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6 [16214923.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):419-20 [16125820.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):108-15 [16708354.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1481-8 [17043014.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2314-20 [17107903.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]
  • [Cites] Cancer Causes Control. 2007 Mar;18(2):135-42 [17235495.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):151-6 [17351903.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4617-26 [17311989.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):43-50 [17906957.001]
  • [Cites] Haematologica. 2008 Mar;93(3):398-404 [18268277.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1850-7 [18347006.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):605-15 [18402527.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Expert Opin Pharmacother. 2008 Jun;9(9):1481-94 [18518779.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix [18954744.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1175-83 [18971419.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):874-80 [11241258.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1610-8 [11250989.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):182-92 [11830608.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3878-84 [12228208.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):74-8 [12556962.001]
  • [Cites] Med Oncol. 2003;20(3):211-20 [14514970.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):383-9 [14746857.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1222-8 [14576060.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1083-91 [15247562.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):565-71 [8636772.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):216-28 [15578683.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):248-55 [19211444.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):873-5 [19620980.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4573-5 [15741224.001]
  • (PMID = 20940199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3020697
  •  go-up   go-down


50. Palefsky J: Biology of HPV in HIV infection. Adv Dent Res; 2006 Apr 01;19(1):99-105
HIV InSite. treatment guidelines - Non-ARV Adverse Events .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The risks for HPV-associated high-grade intra-epithelial neoplasia (IN) and cancer are also increased.
  • The prevalence of oral, anal, and cervical HPV infection in HIV-positive individuals compared with HIV-negative individuals increases with progressively lower CD4+ levels, as does incident high-grade IN.
  • In contrast to IN, development of cancer is not related to lower CD4+ level.
  • With increasing grades of IN and cancer, the proportion of tissues with copy-number abnormalities (CNA) increases, with one of the most common genetic changes being amplification of chromosome 3q.
  • In addition, epigenetic changes occur with increasing frequency in high-grade IN and cancer, such as hypermethylation leading to down-regulation of potential tumor suppressor genes.
  • Persistent high-grade IN and development of cancer may be more strongly related to the cumulative effect of HPV-associated genetic instability and the resulting host genetic changes.
  • There are few data to suggest a direct role for HIV in the pathogenesis of HPV-associated neoplasia, but HIV-associated attenuation of HPV-specific immune responses may allow for persistence of high-grade IN and sufficient time for accumulation of genetic changes that are important in progression to cancer.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / virology. Aneuploidy. Antiretroviral Therapy, Highly Active / adverse effects. Anus Neoplasms / complications. Anus Neoplasms / genetics. Anus Neoplasms / virology. CD4 Lymphocyte Count. Chromosomes, Human, Pair 3 / virology. Female. Humans. Male. Virus Integration

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16672559.001).
  • [ISSN] 1544-0737
  • [Journal-full-title] Advances in dental research
  • [ISO-abbreviation] Adv. Dent. Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5 M01-RR-00079; United States / NCI NIH HHS / CA / CA54053; United States / NIDCR NIH HHS / DE / DE07946; United States / NCI NIH HHS / CA / U01 CA66529; United States / NCI NIH HHS / CA / UO1 CA70019
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 78
  •  go-up   go-down


51. Kim JJ: Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis; 2010 Dec;10(12):845-52
HIV InSite. treatment guidelines - HIV InSite .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A vaccine targeting human papillomavirus (HPV) types 16 and 18, which are associated with 80% of anal cancers, is efficacious in men.
  • METHODS: I constructed decision-analytic models to estimate the direct health and economic outcomes of HPV vaccination (against types 6, 11, 16, and 18) for prevention of HPV-related anal cancer and genital warts.
  • I used the models to conduct sensitivity analyses, including duration of vaccine protection, vaccine cost, and burden of anal cancer and genital warts.
  • Outcomes were most sensitive to variations in anal cancer incidence, duration of vaccine protection, and HIV prevalence in MSM.
  • INTERPRETATION: HPV vaccination of MSM is likely to be a cost-effective intervention for the prevention of genital warts and anal cancer.
  • FUNDING: US National Cancer Institute.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Lancet. 2007 Jun 2;369(9576):1861-8 [17544766.001]
  • [Cites] J Public Health (Oxf). 2008 Sep;30(3):293-304 [18559368.001]
  • [Cites] Med Decis Making. 2002 Sep-Oct;22(5):417-30 [12365484.001]
  • [Cites] Clin Infect Dis. 2003 Jun 1;36(11):1397-403 [12766834.001]
  • [Cites] Value Health. 2004 Sep-Oct;7(5):518-28 [15367247.001]
  • [Cites] Med Decis Making. 1993 Apr-Jun;13(2):89-102 [8483408.001]
  • [Cites] Med Care. 1998 Jun;36(6):778-92 [9630120.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2005 Jun 24;54(24):597-601 [15973239.001]
  • [Cites] Med Decis Making. 2005 Nov-Dec;25(6):667-77 [16282217.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/35-41 [16950016.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):7-28 [17237032.001]
  • [Cites] MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24 [17380109.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):57-63 [19339940.001]
  • [Cites] Sex Transm Dis. 2009 Aug;36(8):515-21 [19543143.001]
  • [Cites] Lancet. 2009 Jul 25;374(9686):301-14 [19586656.001]
  • [Cites] Curr Med Res Opin. 2009 Oct;25(10):2343-51 [19650749.001]
  • [Cites] BMJ. 2009;339:b3884 [19815582.001]
  • [Cites] Health Econ. 2010 Apr;19(4):422-37 [19382128.001]
  • [Cites] J Adolesc Health. 2010 Apr;46(4 Suppl):S12-9 [20307839.001]
  • [Cites] Sex Transm Dis. 2010 Jun;37(6):399-405 [20473245.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):630-2 [20508594.001]
  • [Cites] BMJ. 2010;341:c3493 [20647284.001]
  • [Cites] Vaccine. 2010 Aug 31;28(38):6247-55 [20643092.001]
  • [Cites] Hum Vaccin. 2009 Oct;5(10):696-704 [19855170.001]
  • [Cites] Vaccine. 2010 Oct 4;28(42):6858-67 [20713101.001]
  • [Cites] Cancer. 2010 Dec 1;116(23):5507-16 [20672354.001]
  • [Cites] Sex Transm Infect. 2009 Apr;85(2):148-9 [19153110.001]
  • [Cites] Am J Obstet Gynecol. 2008 May;198(5):500.e1-7 [18455524.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] BMJ. 2008;337:a769 [18640957.001]
  • [CommentIn] Lancet Infect Dis. 2010 Dec;10(12):815-6 [21051294.001]
  • (PMID = 21051295.001).
  • [ISSN] 1474-4457
  • [Journal-full-title] The Lancet. Infectious diseases
  • [ISO-abbreviation] Lancet Infect Dis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093435; United States / NCI NIH HHS / CA / R01 CA93435
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Other-IDs] NLM/ NIHMS561569; NLM/ PMC3982926
  •  go-up   go-down


52. Sivakumaran H, van der Horst A, Fulcher AJ, Apolloni A, Lin MH, Jans DA, Harrich D: Arginine methylation increases the stability of human immunodeficiency virus type 1 Tat. J Virol; 2009 Nov;83(22):11694-703
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The stabilizing action of PRMT6 could allow Tat to persist within the cell and the extracellular environment and thereby enable functions implicated in AIDS-related cancer, neurodegeneration, and T-cell death.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2006 Jan 27;124(2):381-92 [16439211.001]
  • [Cites] Retrovirology. 2009;6:1 [19128510.001]
  • [Cites] Mol Cell. 2006 Apr 7;22(1):51-62 [16600869.001]
  • [Cites] Microbes Infect. 2006 Apr;8(5):1347-57 [16697675.001]
  • [Cites] Retrovirology. 2006;3:48 [16893449.001]
  • [Cites] J Cell Biol. 2006 Nov 6;175(3):401-13 [17088425.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(1):120-34 [17043108.001]
  • [Cites] Nature. 2007 Jan 11;445(7124):214-8 [17215844.001]
  • [Cites] Retrovirology. 2006;3:93 [17176473.001]
  • [Cites] Mol Cell. 2007 Feb 9;25(3):369-83 [17289585.001]
  • [Cites] J Virol. 2007 Apr;81(8):4226-34 [17267505.001]
  • [Cites] AIDS. 2007 Apr 23;21(7):795-805 [17415034.001]
  • [Cites] Mol Cell. 2007 Jun 22;26(6):831-42 [17588518.001]
  • [Cites] Mol Cell. 2007 Jun 22;26(6):843-52 [17588519.001]
  • [Cites] Curr HIV Res. 2007 Sep;5(5):473-83 [17896967.001]
  • [Cites] Nature. 2007 Oct 18;449(7164):933-7 [17898714.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):6106-18 [10545121.001]
  • [Cites] Mol Ther. 2000 Oct;2(4):404-14 [11020357.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28179-84 [11384967.001]
  • [Cites] Mol Cell Biol. 2001 Dec;21(23):7956-70 [11689688.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3537-43 [11724789.001]
  • [Cites] EMBO J. 2002 Jul 1;21(13):3516-25 [12093752.001]
  • [Cites] J Cell Physiol. 2002 Aug;192(2):209-15 [12115727.001]
  • [Cites] Nat Biotechnol. 2003 Aug;21(8):921-6 [12872131.001]
  • [Cites] Nat Cell Biol. 2003 Aug;5(8):754-61 [12883554.001]
  • [Cites] Gene. 2004 Feb 4;326:1-11 [14729258.001]
  • [Cites] Eur J Clin Invest. 2004 Jan;34(1):57-66 [14984439.001]
  • [Cites] Cell. 2004 Jun 11;117(6):690-1 [15186770.001]
  • [Cites] Mol Cell. 2004 Aug 27;15(4):559-71 [15327772.001]
  • [Cites] J Mol Biol. 1971 Dec 28;62(3):465-77 [5136579.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Nature. 1990 May 3;345(6270):84-6 [2184372.001]
  • [Cites] Biotechniques. 1991 Dec;11(6):739-40, 742-3 [1809326.001]
  • [Cites] J Biol Chem. 1993 May 15;268(14):10501-9 [7683681.001]
  • [Cites] Arch Virol. 1994;137(1-2):149-55 [7979988.001]
  • [Cites] J Biol Chem. 1996 Mar 29;271(13):7844-50 [8631829.001]
  • [Cites] J Immunol. 1996 Aug 1;157(3):974-7 [8757599.001]
  • [Cites] J Biol Chem. 1997 Mar 28;272(13):8145-8 [9079628.001]
  • [Cites] EMBO J. 1997 Mar 17;16(6):1224-35 [9135139.001]
  • [Cites] Cell. 1998 Feb 20;92(4):451-62 [9491887.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):384-9 [9514931.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1998;61:65-131 [9752719.001]
  • [Cites] Virology. 1998 Dec 5;252(1):126-36 [9875323.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):353-60 [15525938.001]
  • [Cites] J Virol. 2005 Jan;79(1):124-31 [15596808.001]
  • [Cites] PLoS Biol. 2005 Feb;3(2):e41 [15719057.001]
  • [Cites] Endocr Rev. 2005 Apr;26(2):147-70 [15479858.001]
  • [Cites] Mol Cell. 2005 Apr 29;18(3):263-72 [15866169.001]
  • [Cites] J Exp Med. 2005 Aug 1;202(3):371-7 [16061726.001]
  • [Cites] J Immunol. 2005 Nov 15;175(10):6402-11 [16272292.001]
  • [Cites] Microbes Infect. 2005 Oct;7(13):1364-9 [16046164.001]
  • [Cites] Science. 2007 Oct 19;318(5849):444-7 [17947579.001]
  • [Cites] Genes Dev. 2007 Dec 15;21(24):3369-80 [18079182.001]
  • [Cites] Retrovirology. 2008;5:40 [18498648.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1433-9 [18418067.001]
  • [Cites] Biochim Biophys Acta. 2008 Sep;1780(9):1062-9 [18573314.001]
  • [Cites] Retrovirology. 2008;5:63 [18620576.001]
  • [Cites] J Biol Chem. 2006 Feb 17;281(7):3764-72 [16293633.001]
  • (PMID = 19726520.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / tat Gene Products, Human Immunodeficiency Virus; 94ZLA3W45F / Arginine; EC 2.1.1.- / PRMT6 protein, human; EC 2.1.1.- / Protein-Arginine N-Methyltransferases
  • [Other-IDs] NLM/ PMC2772670
  •  go-up   go-down


53. Reekie J, Kosa C, Engsig F, Monforte Ad, Wiercinska-Drapalo A, Domingo P, Antunes F, Clumeck N, Kirk O, Lundgren JD, Mocroft A, EuroSIDA Study Group: Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer; 2010 Nov 15;116(22):5306-15
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In the combined antiretroviral therapy (cART) era, non-acquired immunodeficiency syndrome (AIDS)-defining malignancies account for more morbidity and mortality in human immunodeficiency virus-infected patients than AIDS-defining malignancies.
  • However, conflicting data have been reported on the relationship between immunodeficiency and the development of some non-AIDS-defining malignancies.
  • Malignancies were classified as virus-related, non-virus-related epithelial, and other.
  • The incidence of non-AIDS-defining malignancies was calculated stratified by current CD4 count.
  • Poisson regression was used to investigate factors associated with the development of non-AIDS-defining malignancies.
  • RESULTS: A total of 356 non-AIDS-defining malignancies occurred, with an incidence rate of 4.3 per 1000 person years of follow-up (95% confidence interval [CI], 3.8-4.7); 172 (48.3%) were virus-related, 135 (37.9%) were non-virus-related epithelial, and 49 (13.7%) were classified as other.
  • Anal (69 cases), lung (31 cases), and melanoma (13 cases), respectively, were the most common non-AIDS-defining malignancies within each group.
  • After adjustment, current CD4 was associated with virus-related non-AIDS-defining malignancies (incidence rate ratio [IRR], 0.81 per doubling; 95% CI, 0.75-0.88; P < .0001) and non-virus-related epithelial non-AIDS-defining malignancies (IRR, 0.84; 95% CI, 0.75-0.95; P = .004), but not with other non-AIDS-defining malignancies (IRR, 1.04; 95% CI, 0.83-1.31; P = .73).
  • Current CD4 count was also associated with anal cancer (IRR, 0.86; 95% CI, 0.75-0.99; P = .03), Hodgkin lymphoma (n = 52; IRR, 0.83; 95% CI, 0.73-0.95; P = .005), and lung cancer (IRR, 0.76; 95% CI, 0.64-0.90; P = .0002).
  • CONCLUSIONS: A low current CD4 count was associated with an increased incidence of certain non-AIDS-defining malignancies.
  • Starting cART earlier to reduce the proportion of patients with a low CD4 count may decrease the rate of developing many common non-AIDS-related malignancies.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20661911.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Losso M; Elias C; Vetter N; Zangerle R; Karpov I; Vassilenko A; Mitsura VM; Suetnov O; Clumeck N; De Wit S; Delforge M; Colebunders R; Vanderkerckhove L; Hadziosmanovic V; Kostov K; Begovac J; Machala L; Rozsypal H; Sedlacek D; Nielsen J; Kronborg G; Benfield T; Larsen M; Gerstoft J; Katzenstein T; Hansen A-; Skinhoj P; Pedersen C; Larsen OD; Oestergaard L; Zilmer K; Smidt J; Ristola M; Katlama C; Viard J-; Girard P-; Livrozet JM; Vanhems P; Pradier C; Dabis F; Neau D; Rockstroh J; Schmidt R; van Lunzen J; Degen O; Stellbrink HJ; Staszewski S; Bogner J; Fatkenheuer G; Kosmidis J; Gargalianos P; Xylomenos G; Perdios J; Panos G; Filandras A; Karabatsaki E; Sambatakou H; Banhegyi D; Mulcahy F; Yust I; Turner D; Burke M; Pollack S; Hassoun G; Mayyan S; Vella S; Esposito R; Mazeau I; Mussini C; Arici C; Pristera R; Mazzotta F; Gabbuti A; Vullo V; Lichtner M; Chirianni A; Montesarchio E; Gargiulo M; Antonucci G; Iacomi F; Narciso P; Vlassi C; Zacarelli M; Lazzarin A; Finazzi R; Galli M; Ridolfo A; d'Arminio Monforte A; Rozental B; Zeltina I; Chaplinskas S; Hemmer R; Staub T; Reiss P; Ormaasen V; Maeland A; Bruun J; Knysz B; Gasiorowski J; Horban A; Bakowska E; Grzeszczuk A; Flisiak R; Boron-Kaczmarska A; Pynka M; Parczewski M; Beniowski M; Mularska E; Trocha H; Jablonowska E; Malolepsza E; Wojcik K; Antunes F; Valadas E; Mansinho K; Maltez F; Duiculescu D; Rakhmanova A; Vinogradova E; Buzunova S; Jevtovic D; Mokras M; Stanekova D; Tomazic J; Gonzalez-Lahoz J; Soriano V; Labarga P; Medrano J; Moreno S; Clotet B; Jou A; Paredes R; Tural C; Puig J; Bravo I; Gatell JM; Miro JM; Domingo P; Gutierrez M; Mateo G; Sambeat MA; Karlsson A; Flamholc L; Ledergerber B; Weber R; Francioli P; Cavassini M; Hirschel B; Boffi E; Furrer H; Battegay M; Elzi L; Kravchenko E; Chentsova N; Kutsyna G; Servitskiy S; Antoniak S; Krasnov M; Barton S; Johnson AM; Mercey D; Phillips A; Johnson MA; Mocroft A; Murphy M; Weber J; Scullard G; Fisher M; Leen C
  •  go-up   go-down


54. Sirera G, Videla S, Piñol M, Cañadas MP, Llatjos M, Ballesteros AL, García-Cuyás F, Castellá E, Guerola R, Tural C, Rey-Joly C, Clotet B: High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men. AIDS; 2006 May 12;20(8):1201-4
MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIV infection is linked with a higher prevalence of anal HPV infection.
  • It is important to assess whether HPV is present in other body parts involved in sexual practices to establish a cancer prevention program.
  • [MeSH-major] AIDS-Related Opportunistic Infections / complications. Papillomaviridae / isolation & purification. Papillomavirus Infections / complications

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16691074.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


55. Fichorova RN, Zhou F, Ratnam V, Atanassova V, Jiang S, Strick N, Neurath AR: Anti-human immunodeficiency virus type 1 microbicide cellulose acetate 1,2-benzenedicarboxylate in a human in vitro model of vaginal inflammation. Antimicrob Agents Chemother; 2005 Jan;49(1):323-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sexual transmission of human immunodeficiency virus type 1 (HIV-1) is facilitated by inflammation and related epithelial barrier perturbation.
  • Cellulose acetate 1,2-benzenedicarboxylate, also named CAP (for "controls AIDS pandemic"), is an anti-HIV-1 microbicide selected from pharmaceutical excipients that are regarded as safe for oral administration but have not been assessed for potential effects on inflammatory factors in the vaginal environment.

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Vaginitis.
  • HIV InSite. treatment guidelines - Women and HIV .
  • Hazardous Substances Data Bank. NONOXYNOLS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Infect Dis. 2001;1:17 [11602021.001]
  • [Cites] Virology. 2003 Mar 1;307(1):122-34 [12667820.001]
  • [Cites] Lancet. 2002 Sep 28;360(9338):971-7 [12383665.001]
  • [Cites] J Virol. 2002 Nov;76(22):11570-83 [12388718.001]
  • [Cites] Sex Transm Dis. 1992 Mar-Apr;19(2):61-77 [1595015.001]
  • [Cites] EMBO J. 1993 Oct;12(10):3879-91 [8404856.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):108-12 [7506410.001]
  • [Cites] J Am Acad Dermatol. 1994 Apr;30(4):535-46 [7512582.001]
  • [Cites] Life Sci. 1994;55(7):533-40 [8041231.001]
  • [Cites] J Am Soc Nephrol. 1994 Aug;5(2):138-52 [7993993.001]
  • [Cites] Br J Cancer. 1995 May;71(5):1018-24 [7734293.001]
  • [Cites] Cell. 1995 Sep 8;82(5):721-32 [7545543.001]
  • [Cites] Cytokine. 1995 Aug;7(6):568-74 [8580374.001]
  • [Cites] Epithelial Cell Biol. 1995;4(1):25-34 [8563793.001]
  • [Cites] J Biol Chem. 1996 Aug 23;271(34):20820-7 [8702837.001]
  • [Cites] Int J STD AIDS. 1996;7 Suppl 2:17-24 [8799790.001]
  • [Cites] Immunopharmacology. 1996 Oct;35(1):1-21 [8913790.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1654-64 [9057648.001]
  • [Cites] N Engl J Med. 1997 Apr 10;336(15):1066-71 [9091804.001]
  • [Cites] Infect Immun. 1997 Jun;65(6):2175-82 [9169748.001]
  • [Cites] Am J Epidemiol. 1997 Aug 15;146(4):350-7 [9270414.001]
  • [Cites] Biol Reprod. 1997 Oct;57(4):847-55 [9314589.001]
  • [Cites] Am J Obstet Gynecol. 1997 Nov;177(5):1230-7 [9396923.001]
  • [Cites] J Clin Invest. 1998 Mar 1;101(5):1163-74 [9486988.001]
  • [Cites] Int J Biochem Cell Biol. 1997 Dec;29(12):1433-48 [9570137.001]
  • [Cites] Toxicology. 1998 Aug 21;129(2-3):193-200 [9772097.001]
  • [Cites] J Infect Dis. 1998 Nov;178(5):1343-51 [9780254.001]
  • [Cites] N Engl J Med. 1998 Dec 17;339(25):1803-9 [9854115.001]
  • [Cites] Biol Reprod. 1999 Feb;60(2):508-14 [9916021.001]
  • [Cites] Biologicals. 1999 Mar;27(1):11-21 [10441398.001]
  • [Cites] J Immunol. 2000 Mar 15;164(6):3353-9 [10706730.001]
  • [Cites] Chest. 2000 Aug;118(2):503-8 [10936147.001]
  • [Cites] JAMA. 2000 Aug 23-30;284(8):949 [10944622.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Nov;44(11):3199-202 [11036053.001]
  • [Cites] Anal Biochem. 2001 Jan 1;288(1):102-4 [11141313.001]
  • [Cites] Obstet Gynecol. 2001 Feb;97(2):211-9 [11165584.001]
  • [Cites] Toxicology. 2001 Feb 2;158(1-2):51-8 [11164992.001]
  • [Cites] J Virol. 2001 Jul;75(13):5812-22 [11390582.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2390-400 [11402335.001]
  • [Cites] J Infect Dis. 2001 Aug 15;184(4):418-28 [11471099.001]
  • [Cites] J Virol. 2001 Sep;75(17):8195-202 [11483765.001]
  • [Cites] Infect Immun. 2001 Sep;69(9):5840-8 [11500462.001]
  • [Cites] Virology. 1995 Apr 1;208(1):197-206 [11831701.001]
  • [Cites] J Immunol. 2002 Mar 1;168(5):2424-32 [11859134.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Aug;11(8):1077-97 [12150703.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Aug-Oct;13(4-5):323-40 [12220547.001]
  • [Cites] J Immunol. 2003 Oct 1;171(7):3751-61 [14500675.001]
  • [Cites] Med Clin North Am. 2003 Sep;87(5):971-95 [14621327.001]
  • [Cites] Am J Obstet Gynecol. 2003 Nov;189(5):1433-8 [14634582.001]
  • [Cites] Nat Rev Microbiol. 2003 Oct;1(1):25-34 [15040177.001]
  • [Cites] Biol Reprod. 2004 Sep;71(3):761-9 [15128598.001]
  • [Cites] Cell. 1984 Jan;36(1):51-60 [6607118.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Sep;85(18):6944-8 [3413127.001]
  • [Cites] J Clin Invest. 1990 May;85(5):1694-7 [2139669.001]
  • [Cites] Science. 1991 Nov 8;254(5033):815-20 [1658933.001]
  • [Cites] J Exp Med. 1991 Dec 1;174(6):1557-63 [1836013.001]
  • [Cites] Mol Hum Reprod. 2003 Jan;9(1):53-8 [12529421.001]
  • [Cites] BMC Infect Dis. 2002 Nov 21;2:27 [12445331.001]
  • [Cites] BMC Infect Dis. 2002 Apr 30;2:6 [11983022.001]
  • (PMID = 15616312.001).
  • [ISSN] 0066-4804
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / P01 HD041761; United States / NICHD NIH HHS / HD / 1P01HD041761
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Cytokines; 0 / Tumor Necrosis Factor-alpha; 0 / cellulose acetate 1,2-benzenedicarboxylate; 26027-38-3 / Nonoxynol; 9004-34-6 / Cellulose
  • [Other-IDs] NLM/ PMC538889
  •  go-up   go-down


56. Reiter PL, Brewer NT, McRee AL, Gilbert P, Smith JS: Acceptability of HPV vaccine among a national sample of gay and bisexual men. Sex Transm Dis; 2010 Mar;37(3):197-203
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Due to higher rates of human papillomavirus (HPV) infection and anal cancer among gay and bisexual men, we aimed to characterize their willingness to get HPV vaccine and identify correlates of vaccine acceptability.
  • Acceptability was also higher among men who reported 5 or more lifetime sexual partners (OR = 3.39, 95% CI: 1.34-8.55), perceived greater severity of HPV-related disease (OR = 1.92, 95% CI: 1.18-3.14), perceived higher levels of HPV vaccine effectiveness (OR = 1.97, 95% CI: 1.27-3.06), or reported higher levels of anticipated regret if they did not get vaccinated and later developed an HPV infection (OR = 2.39, 95% CI: 1.57-3.61).

  • MedlinePlus Health Information. consumer health - Gay, Lesbian, Bisexual, and Transgender Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2008 Jun 15;197(12):1676-84 [18426367.001]
  • [Cites] J Womens Health (Larchmt). 2008 May;17(4):539-48 [18370586.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2036-43 [18708396.001]
  • [Cites] J Adolesc Health. 2008 Oct;43(4 Suppl):S61-7 [18809147.001]
  • [Cites] J Low Genit Tract Dis. 2008 Oct;12(4):276-81 [18820541.001]
  • [Cites] Vaccine. 2008 Aug 19;26 Suppl 10:K68-75 [18847559.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):3036-46 [18980286.001]
  • [Cites] Public Health. 2008 Dec;122(12):1295-301 [18619631.001]
  • [Cites] Sex Transm Dis. 2009 Jan;36(1):58-62 [18830138.001]
  • [Cites] J Am Board Fam Med. 2009 Jan-Feb;22(1):34-42 [19124631.001]
  • [Cites] Vaccine. 2008 Dec 2;26(51):6529-41 [18805453.001]
  • [Cites] Sex Transm Infect. 2009 Apr;85(2):148-9 [19153110.001]
  • [Cites] Obstet Gynecol Clin North Am. 2009 Mar;36(1):187-200 [19344856.001]
  • [Cites] Soc Sci Med. 2009 Aug;69(3):475-80 [19540642.001]
  • [Cites] Am J Mens Health. 2011 Jul;5(4):297-305 [20798149.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Arch Sex Behav. 2004 Dec;33(6):585-91 [15483372.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] J Clin Microbiol. 1995 Aug;33(8):2058-63 [7559948.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]
  • [Cites] Acta Derm Venereol. 2005;85(5):437-43 [16159738.001]
  • [Cites] Int J STD AIDS. 2005 Oct;16(10):707-8 [16212721.001]
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1044-57 [16991079.001]
  • [Cites] Sex Transm Dis. 2007 Mar;34(3):170-3 [16837830.001]
  • [Cites] MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24 [17380109.001]
  • [Cites] Prev Med. 2007 Aug-Sep;45(2-3):107-14 [17628649.001]
  • [Cites] J Infect Dis. 2007 Oct 15;196(8):1137-45 [17955431.001]
  • [Cites] J Infect Dis. 2007 Nov 15;196(10):1431-2 [18008218.001]
  • [Cites] J Adolesc Health. 2008 Mar;42(3):237-42 [18295131.001]
  • [Cites] J Am Coll Health. 2008 Jul-Aug;57(1):23-32 [18682342.001]
  • (PMID = 20118831.001).
  • [ISSN] 1537-4521
  • [Journal-full-title] Sexually transmitted diseases
  • [ISO-abbreviation] Sex Transm Dis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA057726; United States / NCI NIH HHS / CA / R25 CA57726
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Other-IDs] NLM/ NIHMS578642; NLM/ PMC4018212
  •  go-up   go-down


57. Jong E, van Gorp EC, Mulder JW, Tol A, Smits PH: Effect of HIV viral load, CD4 cell count and antiretroviral therapy on human papillomavirus prevalence in urine samples of HIV-infected men. Int J STD AIDS; 2009 Apr;20(4):262-4
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIV-infected patients are at increased risk for persistent human papillomavirus (HPV) infection, the major cause of anogenital cancer.
  • Further prospective studies are needed to determine the role of HPV DNA testing in urine in future screening programmes for anal cancer in men.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. AIDS-Related Opportunistic Infections / urine. Anti-Retroviral Agents / therapeutic use. HIV Infections / drug therapy. HIV Infections / immunology. Papillomavirus Infections / epidemiology. Papillomavirus Infections / urine

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19304972.001).
  • [ISSN] 0956-4624
  • [Journal-full-title] International journal of STD & AIDS
  • [ISO-abbreviation] Int J STD AIDS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / DNA, Viral; 0 / Reverse Transcriptase Inhibitors
  •  go-up   go-down


58. Lopes de Campos WR, Coopusamy D, Morris L, Mayosi BM, Khati M: Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals. Antimicrob Agents Chemother; 2009 Jul;53(7):3056-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The long-term cumulative cytotoxicity of antiretrovirals (ARVs) is among the major causes of treatment failure in patients infected with human immunodeficiency virus (HIV) and patients with AIDS.
  • These data support the development of B40 and related EI aptamers as new ARVs with no cytotoxicity at the estimated potential therapeutic dose.

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Drug Metab. 2007 Jun;8(5):407-47 [17584015.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2007 Oct;34(10):1051-7 [17714093.001]
  • [Cites] J Antimicrob Chemother. 2007 Dec;60(6):1195-205 [17890281.001]
  • [Cites] J Cardiometab Syndr. 2008 Spring;3(2):106-10 [18453811.001]
  • [Cites] Comp Biochem Physiol B Biochem Mol Biol. 2008 Sep;151(1):10-27 [18602321.001]
  • [Cites] Virology. 2008 Nov 10;381(1):46-54 [18799178.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Oct;47(10):3123-9 [14506019.001]
  • [Cites] Nat Rev Drug Discov. 2003 Oct;2(10):812-22 [14526384.001]
  • [Cites] J Virol. 2003 Dec;77(23):12692-8 [14610191.001]
  • [Cites] Am J Ther. 2004 Jul-Aug;11(4):262-77 [15266218.001]
  • [Cites] Curr Med Chem. 2004 Aug;11(15):1983-93 [15279562.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7426-31 [15492266.001]
  • [Cites] Eur J Pharmacol. 1975 Nov;34(1):181-7 [1241962.001]
  • [Cites] Psychopharmacology (Berl). 1978 Apr 14;57(1):33-8 [96466.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096-100 [2413459.001]
  • [Cites] J Histochem Cytochem. 1987 Jan;35(1):23-32 [3025289.001]
  • [Cites] Biochem Pharmacol. 1988 Oct 1;37(19):3543-8 [3178868.001]
  • [Cites] Biochem Pharmacol. 1989 Mar 15;38(6):901-5 [2495009.001]
  • [Cites] Science. 1990 Apr 20;248(4953):358-61 [2183354.001]
  • [Cites] J Neurochem. 1990 Oct;55(4):1166-9 [2398352.001]
  • [Cites] Science. 1990 Dec 7;250(4986):1411-3 [1701568.001]
  • [Cites] J Neural Transm Suppl. 1990;32:41-7 [2089104.001]
  • [Cites] Ann Intern Med. 1992 Feb 15;116(4):311-3 [1733387.001]
  • [Cites] Antimicrob Agents Chemother. 1992 Apr;36(4):733-9 [1380229.001]
  • [Cites] Circ Res. 1994 Feb;74(2):344-8 [8293572.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4096-100 [8171040.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9770-4 [7937889.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2484-8 [7708670.001]
  • [Cites] Nat Med. 1995 May;1(5):417-22 [7585087.001]
  • [Cites] Antimicrob Agents Chemother. 1995 Dec;39(12):2602-5 [8592986.001]
  • [Cites] Antimicrob Agents Chemother. 1996 Feb;40(2):292-7 [8834868.001]
  • [Cites] Life Sci. 1996;59(16):1341-9 [8876663.001]
  • [Cites] Antimicrob Agents Chemother. 1997 Jun;41(6):1250-5 [9174179.001]
  • [Cites] Oncogene. 1998 Jan 22;16(3):369-80 [9467962.001]
  • [Cites] Antimicrob Agents Chemother. 1998 Mar;42(3):612-7 [9517941.001]
  • [Cites] AIDS. 1998 May 7;12(7):F51-8 [9619798.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1881-3 [9652687.001]
  • [Cites] AIDS. 1999 Nov 12;13(16):2311-2 [10563722.001]
  • [Cites] J Histochem Cytochem. 2000 Jan;48(1):147-51 [10653595.001]
  • [Cites] AIDS. 2000 Feb 18;14(3):F25-32 [10716495.001]
  • [Cites] Clin Ther. 2000 Jun;22(6):685-708 [10929917.001]
  • [Cites] Lancet. 2000 Oct 21;356(9239):1423-30 [11052597.001]
  • [Cites] J Anal Toxicol. 2001 Mar;25(2):147-51 [11300508.001]
  • [Cites] Pharm Res. 2000 Dec;17(12):1503-10 [11303960.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7320-6 [11058599.001]
  • [Cites] Chem Res Toxicol. 2001 Jun;14(6):611-50 [11409933.001]
  • [Cites] J HIV Ther. 2001 Mar;6(1):13-6 [11501196.001]
  • [Cites] AIDS. 2001 Jul 27;15(11):1450-2 [11504973.001]
  • [Cites] Chem Res Toxicol. 2001 Sep;14(9):1139-62 [11559028.001]
  • [Cites] HIV Med. 2001 Jul;2(3):163-5 [11737396.001]
  • [Cites] Retina. 2002 Apr;22(2):143-52 [11927845.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6901-8 [12460905.001]
  • [Cites] Ophthalmology. 2003 May;110(5):979-86 [12750101.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2656-68 [12826641.001]
  • [Cites] J Virol. 1998 Sep;72(9):7532-41 [9696850.001]
  • [Cites] AIDS. 1998 Nov 12;12(16):2161-7 [9833857.001]
  • [Cites] Lancet. 1999 Sep 25;354(9184):1112-5 [10509516.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2805-16 [15625332.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Feb;312(2):583-91 [15523003.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Jun;49(6):2314-21 [15917527.001]
  • [Cites] RNA. 2005 Jun;11(6):873-84 [15923374.001]
  • [Cites] Cell Death Differ. 2005 Aug;12 Suppl 1:924-31 [15761470.001]
  • [Cites] Int J Antimicrob Agents. 2005 Jul;26(1):88-91 [15878262.001]
  • [Cites] J Virol. 2005 Nov;79(21):13806-10 [16227301.001]
  • [Cites] Curr Pharm Des. 2005;11(29):3847-52 [16305515.001]
  • [Cites] Pharmacol Biochem Behav. 2005 Nov;82(3):488-94 [16298423.001]
  • [Cites] Clin Ther. 2006 Jan;28(1):36-44 [16490578.001]
  • [Cites] AIDS. 2006 Jul 13;20(11):1497-502 [16847404.001]
  • [Cites] Pharmacol Ther. 2006 Nov;112(2):564-87 [16824612.001]
  • [Cites] Environ Mol Mutagen. 2007 Apr-May;48(3-4):166-72 [16758472.001]
  • (PMID = 19364860.001).
  • [ISSN] 1098-6596
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Aptamers, Nucleotide; 0 / DNA, Mitochondrial; 0 / DNA, Viral; 0 / HIV Envelope Protein gp120; 0 / HIV Integrase Inhibitors; 0 / HIV Protease Inhibitors; 0 / Reverse Transcriptase Inhibitors; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A; EC 1.4.3.4 / Monoamine Oxidase; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7
  • [Other-IDs] NLM/ PMC2704642
  •  go-up   go-down


59. Cullen MD, Sarkar T, Hamel E, Hartman TL, Watson KM, Buckheit RW Jr, Pannecouque C, De Clercq E, Cushman M: Inhibition of tubulin polymerization by select alkenyldiarylmethanes. Bioorg Med Chem Lett; 2008 Jan 15;18(2):469-73
Hazardous Substances Data Bank. METHANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the ADAMs are structurally related to the tubulin polymerization inhibitor CC-5079, a set of 14 ADAMs were tested for inhibition of tubulin polymerization in an attempt to identify the biological target responsible for their cytotoxicity.
  • Both compounds were investigated for anticancer activity in the National Cancer Institute's panel of 60 human cancer cell lines, and both compounds consistently displayed submicromolar cytotoxicities with mean-graph midpoint (MGM) values of 0.31+/-0.08 and 0.47+/-0.09 microM, respectively.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 1984 Aug 28;23(18):4173-84 [6487596.001]
  • [Cites] Cancer Chemother Biol Response Modif. 2003;21:41-67 [15338740.001]
  • [Cites] J Biol Chem. 1992 Dec 25;267(36):25988-97 [1281479.001]
  • [Cites] Adv Pharmacol. 1995;33:389-438 [7495676.001]
  • [Cites] J Med Chem. 1996 Aug 2;39(16):3217-27 [8759644.001]
  • [Cites] Biochemistry. 1997 Nov 18;36(46):14056-63 [9369477.001]
  • [Cites] Retrovirology. 2005;2:7 [15698476.001]
  • [Cites] J Med Chem. 2005 Sep 22;48(19):6140-55 [16162014.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):951-9 [16424030.001]
  • [Cites] J Med Chem. 2007 Jul 12;50(14):3314-21 [17579385.001]
  • [Cites] J Med Chem. 2007 Oct 4;50(20):4854-67 [17803290.001]
  • [Cites] J Med Chem. 1999 Nov 18;42(23):4861-74 [10579849.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:89-111 [11031231.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6711-9 [11096104.001]
  • [Cites] J Med Chem. 2001 Nov 22;44(24):4092-113 [11708913.001]
  • [Cites] AIDS Anal Afr. 2000 Feb-Mar;10(5):2 [12322486.001]
  • [Cites] Cell Biochem Biophys. 2003;38(1):1-22 [12663938.001]
  • [Cites] J Med Chem. 2004 Jun 3;47(12):3149-62 [15163195.001]
  • [Cites] J Virol Methods. 1988 Aug;20(4):309-21 [2460479.001]
  • (PMID = 18083556.001).
  • [ISSN] 1464-3405
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI043637-06; United States / NIAID NIH HHS / AI / R01-AI-43637; United States / NIAID NIH HHS / AI / R01 AI043637; United States / PHS HHS / / C06-14499; United States / NIAID NIH HHS / AI / R01 AI043637-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biopolymers; 0 / Reverse Transcriptase Inhibitors; 0 / Tubulin; EC 2.7.7.- / reverse transcriptase, Human immunodeficiency virus 1; EC 2.7.7.49 / HIV Reverse Transcriptase; OP0UW79H66 / Methane
  • [Other-IDs] NLM/ NIHMS39752; NLM/ PMC2255563
  •  go-up   go-down


60. Cresti S, Ouaïssi M, Sielezneff I, Chaix JB, Pirro N, Berthet B, Consentino B, Sastre B: Advantage of vacuum assisted closure on healing of wound associated with omentoplasty after abdominoperineal excision: a case report. World J Surg Oncol; 2008;6:136

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Primary closure of the perineum with drainage after abdominoperineal excision of the rectum for carcinoma, is widely accepted.
  • Those complications are frequently related to the patients' clinical antecedent (i.e radiotherapy, diabetes, smoking).
  • CASE PRESENTATION: In the present report, vacuum assisted drainage was used after abdominoperineal excision for carcinoma in the very first step due to intraoperative gross septic contamination during tumor resection.
  • The first case: A 57-years old man with a 30-years history of peri-anal Crohn's disease, the adenocarcinoma of the lowest part of the rectum and Crohn colitis with multiple area of severe dysplasia required panproctocolectomy with a perineal resection.
  • The second case: A 51-year-old man, with AIDS.
  • An abdominoperineal resection was performed for recurrence epidermoid anal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2008 Apr;206(4):694-703 [18387476.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):438-43 [15719190.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):104-10 [15827789.001]
  • [Cites] Dis Colon Rectum. 2005 Jan;48(1):43-8 [15690656.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1745-8 [15540310.001]
  • [Cites] Br J Plast Surg. 1997 Apr;50(3):194-9 [9176007.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1189-92 [7577019.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):890-6 [8076488.001]
  • [Cites] World J Surg. 1992 May-Jun;16(3):478-85 [1589984.001]
  • [Cites] Colorectal Dis. 2003 Sep;5(5):486-9 [12925086.001]
  • [Cites] Wound Repair Regen. 2004 Jan-Feb;12(1):11-7 [14974959.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1403-7; discussion 1407-8 [15484357.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):476-81; discussion 481-2 [15714245.001]
  • [Cites] Surgery. 2001 Sep;130(3):463-9 [11562671.001]
  • (PMID = 19102785.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2621222
  •  go-up   go-down


61. Herbeuval JP, Grivel JC, Boasso A, Hardy AW, Chougnet C, Dolan MJ, Yagita H, Lifson JD, Shearer GM: CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood; 2005 Nov 15;106(10):3524-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recently reported that plasma levels of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) are elevated in HIV-1-infected patients and that they correlate with viral load.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2002 Aug;76(16):8433-45 [12134046.001]
  • [Cites] J Exp Med. 1997 Oct 20;186(8):1365-72 [9334376.001]
  • [Cites] J Virol. 2003 Jun;77(12):6700-8 [12767990.001]
  • [Cites] Nature. 2003 Jul 31;424(6948):516-23 [12872134.001]
  • [Cites] Nat Immunol. 2003 Sep;4(9):825-6 [12942081.001]
  • [Cites] J Neuroimmunol. 2004 Mar;148(1-2):127-39 [14975593.001]
  • [Cites] AIDS Res Hum Retroviruses. 2004 Feb;20(2):175-82 [15018705.001]
  • [Cites] Curr HIV Res. 2003 Oct;1(4):405-17 [15049427.001]
  • [Cites] Immunogenetics. 2004 Apr;56(1):56-60 [15042330.001]
  • [Cites] J Virol. 2004 May;78(10):5223-32 [15113904.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):761-70 [15365095.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):749-59 [15365096.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Feb;83(3):772-6 [3003749.001]
  • [Cites] J Interferon Res. 1986 Apr;6(2):143-52 [2425014.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Science. 1989 Jul 21;245(4915):305-8 [2665081.001]
  • [Cites] Immunity. 1997 Dec;7(6):821-30 [9430227.001]
  • [Cites] Eur J Immunol. 1998 Jan;28(1):143-52 [9485194.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3851-6 [9520456.001]
  • [Cites] J Virol. 2001 Feb;75(3):1152-64 [11152488.001]
  • [Cites] J Exp Med. 2001 Mar 5;193(5):651-60 [11238596.001]
  • [Cites] Blood. 2001 Aug 15;98(4):906-12 [11493432.001]
  • [Cites] AIDS. 2001 Sep 7;15(13):1603-12 [11546934.001]
  • [Cites] Cytometry. 2001 Sep 1;45(1):37-46 [11598945.001]
  • [Cites] J Virol. 2001 Nov;75(22):11128-36 [11602752.001]
  • [Cites] Eur J Immunol. 2001 Dec;31(12):3513-24 [11745371.001]
  • [Cites] Immunobiology. 2001 Dec;204(5):629-38 [11846228.001]
  • [Cites] Nat Med. 2002 Apr;8(4):319-23 [11927927.001]
  • [Cites] J Exp Med. 1998 Apr 6;187(7):1113-22 [9529327.001]
  • [Cites] J Virol. 1998 Oct;72(10):7992-8001 [9733838.001]
  • [Cites] AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S311-9 [9814959.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):2639-47 [10072506.001]
  • [Cites] Nat Med. 1999 Mar;5(3):344-6 [10086394.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 1;20(4):358-70 [10096580.001]
  • [Cites] J Exp Med. 1999 May 3;189(9):1451-60 [10224285.001]
  • [Cites] Blood. 1999 May 15;93(10):3309-16 [10233883.001]
  • [Cites] Science. 1999 Jun 11;284(5421):1835-7 [10364556.001]
  • [Cites] J Virol. 2005 Mar;79(5):3195-9 [15709041.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2458-64 [15585654.001]
  • [Cites] J Exp Med. 1992 Feb 1;175(2):331-40 [1346269.001]
  • [Cites] J Virol. 1993 Apr;67(4):2182-90 [8445728.001]
  • [Cites] Science. 1993 Mar 19;259(5102):1749-54 [8096089.001]
  • [Cites] Nat Med. 1995 Feb;1(2):129-34 [7585008.001]
  • [Cites] Immunity. 1995 Dec;3(6):673-82 [8777713.001]
  • [Cites] J Immunol. 1997 Mar 1;158(5):2456-63 [9036997.001]
  • [Cites] Science. 1997 Apr 4;276(5309):111-3 [9082980.001]
  • [Cites] Virology. 1997 Mar 31;230(1):134-44 [9126269.001]
  • [Cites] Science. 1997 Aug 8;277(5327):768 [9273698.001]
  • [Cites] J Infect Dis. 1997 Sep;176(3):811-4 [9291341.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):611-21 [12697854.001]
  • (PMID = 16046522.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antibodies; 0 / Apoptosis Regulatory Proteins; 0 / HIV Envelope Protein gp120; 0 / Interferon Type I; 0 / Membrane Glycoproteins; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10B protein, human; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC1895067
  •  go-up   go-down


62. Kreuter A, Hochdorfer B, Brockmeyer NH, Altmeyer P, Pfister H, Wieland U, Competence Network HIV/AIDS: A human papillomavirus-associated disease with disseminated warts, depressed cell-mediated immunity, primary lymphedema, and anogenital dysplasia: WILD syndrome. Arch Dermatol; 2008 Mar;144(3):366-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although skin cancer frequently develops in the sun-exposed cutaneous lesions of patients with EV, the anogenital area is usually not affected by squamous cell carcinomas related to mucosal HPV types.
  • [MeSH-minor] Adult. Anal Canal / pathology. Diagnosis, Differential. Female. Genitalia, Female / pathology. Humans. Papillomaviridae / classification. Papillomaviridae / isolation & purification. Syndrome

  • Genetic Alliance. consumer health - Lymphedema.
  • MedlinePlus Health Information. consumer health - Lymphedema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347293.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Eaton LA, Kalichman SC, Cherry C: Sexual partner selection and HIV risk reduction among Black and White men who have sex with men. Am J Public Health; 2010 Mar;100(3):503-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: We examined differences in sexual partner selection between Black and White men who have sex with men (MSM) to better understand how HIV status of participants' sexual partners and related psychosocial measures influence risk taking among these men.
  • RESULTS: HIV-negative White MSM were more likely than were HIV-negative Black MSM to report having unprotected anal intercourse with HIV-negative men, and HIV-negative Black MSM were more likely than were HIV-negative White MSM to report having unprotected anal intercourse with HIV status unknown partners.
  • CONCLUSIONS: White MSM appear to use sexual partner-related risk reduction strategies to reduce the likelihood of HIV infection more than do Black MSM.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Public Health. 2007 Dec;97(12):2230-7 [17971556.001]
  • [Cites] Am J Prev Med. 2007 Dec;33(6):479-85 [18022064.001]
  • [Cites] AIDS Behav. 2009 Aug;13(4):630-7 [19479369.001]
  • [Cites] Health Psychol. 2000 Mar;19(2):134-45 [10762097.001]
  • [Cites] Health Psychol. 2000 Sep;19(5):496-500 [11007158.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):471-7 [11744837.001]
  • [Cites] AIDS Educ Prev. 2002 Jun;14(3):183-9 [12092920.001]
  • [Cites] Sex Transm Dis. 2002 Dec;29(12):756-62 [12466716.001]
  • [Cites] Ethn Dis. 2003 Winter;13(1):47-54 [12723012.001]
  • [Cites] Ann Behav Med. 2003 Oct;26(2):104-23 [14534028.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):526-36 [15021318.001]
  • [Cites] AIDS Behav. 2004 Jun;8(2):215-20 [15187483.001]
  • [Cites] Perspect Sex Reprod Health. 2004 May-Jun;36(3):114-9 [15306269.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2004 Oct 1;53(38):891-4 [15457144.001]
  • [Cites] Stat Med. 1997 Aug 15;16(15):1695-703 [9265694.001]
  • [Cites] Health Psychol. 1998 Nov;17(6):546-50 [9848805.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):61-8 [15608527.001]
  • [Cites] Health Educ Res. 2005 Feb;20(1):24-35 [15253999.001]
  • [Cites] Dakar Med. 2002;47(2):229-33 [15776682.001]
  • [Cites] Ann Behav Med. 2005 Apr;29(2):86-95; discussion 96-9 [15823781.001]
  • [Cites] AIDS Patient Care STDS. 2005 Nov;19(11):737-44 [16283834.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):142-5 [16434600.001]
  • [Cites] AIDS Care. 2006 Nov;18(8):918-30 [17012081.001]
  • [Cites] Curr HIV/AIDS Rep. 2006 Nov;3(4):160-8 [17032575.001]
  • [Cites] AIDS. 2006 Oct 24;20(16):2081-9 [17053354.001]
  • [Cites] Sex Transm Infect. 2006 Dec;82(6):461-6 [17151031.001]
  • [Cites] AIDS. 2007 Jan;21 Suppl 1:S43-8 [17159586.001]
  • [Cites] Sex Transm Dis. 2007 Apr;34(4):215-9 [17179774.001]
  • [Cites] AIDS Behav. 2007 Sep;11(5):706-15 [17295071.001]
  • [Cites] AIDS. 2007 Oct 1;21(15):2083-91 [17885299.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):212-8 [18769346.001]
  • (PMID = 20075328.001).
  • [ISSN] 1541-0048
  • [Journal-full-title] American journal of public health
  • [ISO-abbreviation] Am J Public Health
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / MH071164-05; United States / NIMH NIH HHS / MH / R01 MH071164-02; United States / NIMH NIH HHS / MH / MH071164-02; United States / NIMH NIH HHS / MH / MH071164-01A1; United States / NIMH NIH HHS / MH / T32 MH074387-01A1; United States / NIMH NIH HHS / MH / T32 MH074387-05; United States / NIMH NIH HHS / MH / R01 MH071164; United States / NIMH NIH HHS / MH / MH071164-04; United States / NIMH NIH HHS / MH / T32 MH074387-03; United States / NIMH NIH HHS / MH / R01 MH071164-03; United States / NIMH NIH HHS / MH / T32- MH074387; United States / NIMH NIH HHS / MH / R01 MH071164-01A1; United States / NIMH NIH HHS / MH / MH074387-02; United States / NIMH NIH HHS / MH / T32 MH074387-04; United States / NIMH NIH HHS / MH / MH071164-03; United States / NIMH NIH HHS / MH / R01 MH071164-04; United States / NIMH NIH HHS / MH / T32 MH074387-02; United States / NIMH NIH HHS / MH / MH074387-01A1; United States / NIMH NIH HHS / MH / R01-MH71164; United States / NIMH NIH HHS / MH / T32 MH074387; United States / NIMH NIH HHS / MH / MH074387-03; United States / NIMH NIH HHS / MH / R01 MH071164-02S1; United States / NIMH NIH HHS / MH / R01 MH071164-05; United States / NIMH NIH HHS / MH / MH071164-02S1
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS230724; NLM/ PMC2820059
  •  go-up   go-down


64. Bonnet F, Chêne G: Evolving epidemiology of malignancies in HIV. Curr Opin Oncol; 2008 Sep;20(5):534-40
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Morbidity and mortality related to malignancy are increasing in HIV-infected patients.
  • We aim at reviewing the literature on recent changes in the incidence of AIDS-defining and non-AIDS-defining malignancies and the specific characteristics of the main cancers emerging in HIV-infected patients.
  • Since the introduction of combination antiretroviral therapy, the incidence of Kaposi's sarcoma and cerebral lymphoma (among AIDS-defining cancers) decreased in parallel with AIDS-defining infections, whereas the incidence of systemic non-Hodgkin's lymphoma and cervical cancer decreased less than others and remains higher in HIV-infected patients than in the general population.
  • The most recent and large studies have also shown a 1.7-3-fold higher risk of developing non-AIDS malignancies in HIV-infected patients as compared with the general population without a significant impact of combination antiretroviral therapy on these trends.
  • These malignancies include Hodgkin's disease, lung, anal, head and neck cancers, hemopathies, and conjunctival cancers.

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106656.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 75
  •  go-up   go-down


65. Menza TW, Hughes JP, Celum CL, Golden MR: Prediction of HIV acquisition among men who have sex with men. Sex Transm Dis; 2009 Sep;36(9):547-55
Hazardous Substances Data Bank. d-METHAMPHETAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A prediction model that included variables indicating use of methamphetamine or inhaled nitrites in the prior 6 months, unprotected anal intercourse with a partner of positive or unknown HIV status in the prior year, > or =10 male sex partners in the prior year, and current diagnosis or history of bacterial sexually transmitted infection was well calibrated overall (expected-observed ratio = 1.01; 95% CI: 0.97, 1.05) and had modest discriminatory accuracy at 1 year (area under the receiver-operator characteristic curve = 0.67; 95% CI: 0.60, 0.75) and at 4 years (area under the receiver-operator characteristic curve = 0.66; 95% CI: 0.61, 0.71).

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2007 May 1;45(1):85-92 [17325605.001]
  • [Cites] Am J Public Health. 2007 Jun;97(6):1060-6 [17463370.001]
  • [Cites] Am J Public Health. 2007 Jun;97(6):1067-75 [17463384.001]
  • [Cites] PLoS Med. 2007 Dec;4(12):e339 [18052602.001]
  • [Cites] Ann Intern Med. 2008 Mar 4;148(5):337-47 [18316752.001]
  • [Cites] JAMA. 2008 Aug 6;300(5):520-9 [18677024.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2008 Sep 12;57(36):985-9 [18784639.001]
  • [Cites] BMJ. 1999 Dec 11;319(7224):1562-5 [10591726.001]
  • [Cites] Diabetes Metab Res Rev. 2000 May-Jun;16(3):164-71 [10867715.001]
  • [Cites] Biometrics. 2000 Jun;56(2):337-44 [10877287.001]
  • [Cites] JAMA. 2001 Jun 13;285(22):2864-70 [11401607.001]
  • [Cites] BMJ. 2001 Jun 16;322(7300):1451-6 [11408300.001]
  • [Cites] JAMA. 2001 Jul 11;286(2):180-7 [11448281.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):373-9 [11707675.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):76-85 [11782594.001]
  • [Cites] J Addict Dis. 2002;21(1):91-105 [11831503.001]
  • [Cites] J Infect Dis. 2002 Oct 1;186(7):1019-22 [12232844.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):202-10 [12394799.001]
  • [Cites] Circulation. 2002 Dec 17;106(25):3143-421 [12485966.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):83S-88S [12527567.001]
  • [Cites] Hypertension. 2003 Dec;42(6):1206-52 [14656957.001]
  • [Cites] Pharmacotherapy. 2004 Jan;24(1):69-78 [14740789.001]
  • [Cites] Am J Epidemiol. 2004 May 1;159(9):882-90 [15105181.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):734-42 [15167293.001]
  • [Cites] Lancet. 2004 Jul 3-9;364(9428):41-50 [15234855.001]
  • [Cites] Sex Transm Dis. 2004 Aug;31(8):475-80 [15273580.001]
  • [Cites] Med J Aust. 1989 Jun 5;150(11):634-9 [2725377.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86 [2593165.001]
  • [Cites] Sex Transm Dis. 1992 Mar-Apr;19(2):61-77 [1595015.001]
  • [Cites] Am J Public Health. 1993 Apr;83(4):520-4 [8460727.001]
  • [Cites] Stat Med. 1996 Feb 28;15(4):361-87 [8668867.001]
  • [Cites] Am J Epidemiol. 1997 Oct 1;146(7):531-42 [9326430.001]
  • [Cites] Stat Med. 1998 Jan 30;17(2):219-38 [9483730.001]
  • [Cites] Am J Public Health. 1998 Jan;88(1):113-6 [9584015.001]
  • [Cites] JAMA. 1998 Oct 7;280(13):1161-7 [9777816.001]
  • [Cites] Sex Transm Dis. 1998 Nov;25(10):539-43 [9858350.001]
  • [Cites] Lancet. 1999 Jan 9;353(9147):89-92 [10023892.001]
  • [Cites] Ann Intern Med. 1999 Mar 16;130(6):515-24 [10075620.001]
  • [Cites] Biometrics. 2005 Mar;61(1):92-105 [15737082.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 May 1;39(1):82-9 [15851918.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):489-95 [16010174.001]
  • [Cites] AIDS. 2005 Aug 12;19(12):1323-5 [16052089.001]
  • [Cites] Ann Intern Med. 2006 Feb 7;144(3):201-9 [16461965.001]
  • [Cites] AIDS. 2006 Mar 21;20(5):731-9 [16514304.001]
  • [Cites] Am J Epidemiol. 2006 Apr 1;163(7):676-83 [16484448.001]
  • [Cites] Circulation. 2006 Aug 15;114(7):e257-354 [16908781.001]
  • [Cites] Am J Epidemiol. 2006 Oct 15;164(8):733-41 [16896053.001]
  • [Cites] AIDS. 2006 Nov 14;20(17):2193-7 [17086059.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):1-6 [17058200.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2615-7 [17182986.001]
  • [Cites] Diabetes Care. 2007 Jan;30 Suppl 1:S48-65 [17192379.001]
  • [Cites] Ann Intern Med. 2007 Apr 3;146(7):511-5 [17404353.001]
  • (PMID = 19707108.001).
  • [ISSN] 1537-4521
  • [Journal-full-title] Sexually transmitted diseases
  • [ISO-abbreviation] Sex Transm Dis
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI007140-21; United States / NIAID NIH HHS / AI / T32 AI007140; United States / NIAID NIH HHS / AI / T32 AI007140-21; United States / NIAID NIH HHS / AI / T32 AI07140
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 44RAL3456C / Methamphetamine
  • [Other-IDs] NLM/ NIHMS126943; NLM/ PMC2753675
  •  go-up   go-down


66. Budihas SR, Gorshkova I, Gaidamakov S, Wamiru A, Bona MK, Parniak MA, Crouch RJ, McMahon JB, Beutler JA, Le Grice SF: Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. Nucleic Acids Res; 2005;33(4):1249-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-throughput screening of a National Cancer Institute library of pure natural products identified the hydroxylated tropolone derivatives beta-thujaplicinol (2,7-dihydroxy-4-1(methylethyl)-2,4,6-cycloheptatrien-1-one) and manicol (1,2,3,4-tetrahydro-5-7-dihydroxy-9-methyl-2-(1-methylethenyl)-6H-benzocyclohepten-6-one) as potent and selective inhibitors of the ribonuclease H (RNase H) activity of human immunodeficiency virus-type 1 reverse transcriptase (HIV-1 RT).
  • In contrast, the related tropolone analog beta-thujaplicin (2-hydroxy-4-(methylethyl)-2,4,6-cycloheptatrien-1-one), which lacks the 7-OH group of the heptatriene ring, was inactive, while manicol, which possesses a 7-OH group, inhibited HIV-1 and E.coli RNases H with IC50 = 1.5 microM and 40 microM, respectively.

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Biochem. 1981 Mar 16;115(1):207-16 [7227366.001]
  • [Cites] Chembiochem. 2004 Apr 2;5(4):527-33 [15185377.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • [Cites] J Antibiot (Tokyo). 1988 Jul;41(7):862-8 [3417559.001]
  • [Cites] J Chromatogr. 1988 Nov 25;455:430-3 [3235623.001]
  • [Cites] J Gen Virol. 1991 Jan;72 ( Pt 1):59-66 [1703563.001]
  • [Cites] Science. 1991 Apr 5;252(5002):88-95 [1707186.001]
  • [Cites] J Med Chem. 1992 Jul 24;35(15):2735-43 [1379639.001]
  • [Cites] J Virol. 1993 Apr;67(4):2412-20 [7680393.001]
  • [Cites] J Biol Chem. 1994 Mar 25;269(12):8803-7 [8132614.001]
  • [Cites] Bioorg Med Chem. 1994 Mar;2(3):169-79 [7522907.001]
  • [Cites] J Biol Chem. 1995 Mar 3;270(9):4861-9 [7533167.001]
  • [Cites] Biochemistry. 1996 Feb 13;35(6):1911-7 [8639674.001]
  • [Cites] Biochemistry. 1997 Mar 18;36(11):3179-85 [9115994.001]
  • [Cites] Antiviral Res. 1998 Aug;39(2):89-100 [9806486.001]
  • [Cites] Biochemistry. 1999 Oct 5;38(40):13070-6 [10529177.001]
  • [Cites] Anal Biochem. 2004 Aug 15;331(2):296-302 [15265735.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2000 Feb;48(2):194-200 [10705503.001]
  • [Cites] J Biol Inorg Chem. 2000 Feb;5(1):67-74 [10766438.001]
  • [Cites] Biol Pharm Bull. 2000 Aug;23(8):995-7 [10963310.001]
  • [Cites] Adv Pharmacol. 2000;49:67-109 [11013761.001]
  • [Cites] Biochemistry. 2000 Nov 21;39(46):14279-91 [11087377.001]
  • [Cites] Methods Mol Biol. 2001;160:335-54 [11265294.001]
  • [Cites] Anal Biochem. 2001 Apr 15;291(2):198-206 [11401293.001]
  • [Cites] Phytother Res. 2001 Nov;15(7):586-8 [11746838.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16689-96 [11875059.001]
  • [Cites] Biol Pharm Bull. 2002 Aug;25(8):981-5 [12186430.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):2777-80 [12480948.001]
  • [Cites] AIDS Rev. 2002 Oct-Dec;4(4):183-94 [12555693.001]
  • [Cites] Mol Cell. 2003 Mar;11(3):807-15 [12667461.001]
  • [Cites] Nucleic Acids Res. 2003 Oct 1;31(19):5776-88 [14500841.001]
  • [Cites] Biol Pharm Bull. 2003 Oct;26(10):1487-90 [14519960.001]
  • [Cites] Nucleic Acids Res. 2003 Dec 1;31(23):6852-9 [14627818.001]
  • [Cites] Anal Biochem. 2003 Nov 1;322(1):33-9 [14705777.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6C):4757-63 [14981923.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):1539-47 [15004241.001]
  • [Cites] Methods Enzymol. 1982;87:500-9 [6757651.001]
  • (PMID = 15741178.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Benzocycloheptenes; 0 / Coumarins; 0 / Pyranocoumarins; 0 / Reverse Transcriptase Inhibitors; 0 / beta-thujaplicinol; 0 / manicol; 7L6DL16P1T / Tropolone; EC 3.1.26.4 / Ribonuclease H; S5A9TQN46W / calanolide A
  • [Other-IDs] NLM/ PMC552956
  •  go-up   go-down


67. Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L, Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H, Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CL, Streicher H, Stroncek DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkuhle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB, Marincola FM: Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med; 2009;7:45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Supported by the Office of International Affairs, National Cancer Institute (NCI), the "US-Japan Workshop on Immunological Biomarkers in Oncology" was held in March 2009.
  • The workshop was related to a task force launched by the International Society for the Biological Therapy of Cancer (iSBTc) and the United States Food and Drug Administration (FDA) to identify strategies for biomarker discovery and validation in the field of biotherapy.
  • The effort will culminate on October 28th 2009 in the "iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer", which will be held in Washington DC in association with the Annual Meeting.
  • The purposes of the US-Japan workshop were a) to discuss novel approaches to enhance the discovery of predictive and/or prognostic markers in cancer immunotherapy;.
  • Converging concepts were identified: enhanced knowledge of interferon-related pathways was found to be central to the understanding of immune-mediated tissue-specific destruction (TSD) of which tumor rejection is a representative facet.
  • It is likely that adaptive immune responses play a broader role in tumor rejection than those strictly related to their antigen-specificity; likely, their primary role is to trigger an acute and tissue-specific inflammatory response at the tumor site that leads to rejection upon recruitment of additional innate and adaptive immune mechanisms.
  • [MeSH-minor] Humans. Japan. National Cancer Institute (U.S.). Reproducibility of Results. United States. United States Food and Drug Administration